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51.0. INTRODUCTION
This thesis addresses two of the most common psychiatric illnesses, namely
Unipolar Major Depression (MDD) and the frequent co-occurrence of anxiety disorder (A).
The presence of co-morbid anxiety disorders in persons with MDD has largely gone 
unexamined, especially regarding the effects on neuropsychological functioning.
The high rates of both MDD and anxiety disorders in the population, make the study of the 
co-occurrence of these two disorders highly relevant and important both for clinicians and the 
society. Both disorders are associated with cognitive/neuropsychological deficits, but separate 
studies of MDD and A has shown conflicting findings related to the functions affected and the 
extent of cognitive deficits. Also, not all patients with MDD display neuropsychological 
deficits, and these mixed results may partly be explained by unaddressed co-morbid anxiety.
The studies we have conducted specifically address the effects of MDD and MDD with co-
morbid anxiety (MDDA) on different neuropsychological measures. Due to the heterogeneity 
and multifactorial symptoms in both MDD and A, and hence MDDA, it is important to 
broaden the understanding of the associated specific neuropsychological dysfunctions.
The clinical implications of cognitive deficits in MDD and A may lead to severe alteration in 
the ability to cope in daily life demands, and be a key factor in occupational functioning and 
the ability to functional recovery (Jaeger et al., 2006). Aspects of cognition highly relevant to 
daily life functioning are: attention, memory functions and executive control.
1.1. Prevalence
Depression and anxiety disorders are among the most frequently occurring mental disorders in 
the general population world wide. However, prevalence estimates vary in different studies, 
and may be due to differences in assessment instruments, classification systems and/or 
sampling procedures.
Depressive disorders present a significant mental health concern to individuals and to our 
society and are among the most frequent occurring mental disorder in the general population.
The lifetime risk for major depressive disorder (MDD) is between 10% and 25% for women 
and between 5% and 12% for men (APA, 1994). Numbers from The World Health Report 
(WHO; 2001) estimate that 5.8 % men and 9.5 % women will experience a depressive 
episode in any given year. According to the National Comorbidity Survey (NCS; Kessler et 
al., 2005) the lifetime prevalence of any anxiety disorders was 31. 2% (female 36.4% and
male 25.4%). The 12-month prevalence for any anxiety disorder is according to the same
6survey was estimated to 19. 1% (Female 23.4% and Male 14.3 %).  Both the lifetime and the 
one-year prevalence of the different anxiety disorders differed considerably, but in general,
the public health impact of having any anxiety disorder should be evident.
MDD with co-morbid anxiety (MDDA) are characterized by diagnosable MDD and A 
according to DSM-IV (or ICD-10). There are extensive co-morbidity between MDD and 
other affective disorders, especially anxiety disorders (A). Both disorders are highly prevalent 
in the population and are associated with high levels of morbidity and mortality as well as 
great economic costs for the society. In individuals with depression or an anxiety disorder, co-
morbidity with the other disorder occurs in one quarter to co-occurrence prevalence rates up 
to 60% in lifetime diagnoses, more specific, 58% of MDD patients were found to have an 
anxiety disorder. (NCS; Kessler et al., 2003; Kessler et al., 2005). But, varying degrees of co-
morbidity between depression and anxiety have been reported in different studies, and vary 
according to the different anxiety disorder (Mineka et al., 1998). In the international WHO 
study (Sartorius et al., 1996) the rates were somewhat lower than in NCS, among cases of 
depression 39% had an anxiety disorder. Still, these numbers suggest that co-morbid anxiety 
and depression are “the rule rather than the exception”.
1.2. Impact on public health 
The Global Burden of Disease Study (GBD) ranked MDD as the fourth most important cause 
of global disability-adjusted life years (DALY; Murray & Lopez, 1997a) and MDD was also 
predicted to advance to the second most important cause by year 2020 (Murray & Lopez, 
1997b). NCS estimated the annual costs of anxiety disorders to be 54 % of the total costs due 
to treatment for somatic illness, and 31 % of the costs due to treatment for mental illness 
(Greenberg et al., 1999)
The fact that co-morbidity between MDD and A is very high, and in clinical practice 
associated with barriers to treatment and worse psychiatric outcomes, such as treatment 
resistance, increased risk for suicide, greater chance for recurrence and greater utilization of 
medical resources, demands a greater attention to and understanding of the disorders trough 
research on different levels. This to positively impact the economic burden of these costly 
disorders on society and the individuals’ daily-life functioning and suffering.
However, much is still unknown about the underlying mechanisms both regarding aetiology,
risk factors, medication, genetics, neurobiology, neuroanatomy, neuronal networks and the 
impact of cognition.
71.3. Diagnostic criteria
Clinicians most often attempt to separate depression from anxiety, and sometimes these 
distinctions are challenging and often artificial (Aina & Susman, 2006). Factors that favour 
anxiety is the emotion of fear involving feelings of tension, worry, apprehension, and fear for 
something considered dangerous in the future, in addition to specific behaviour such as 
avoidance. Factors that favour depression include symptoms like the emotion of sadness, in 
addition to feelings of sorrow, hopelessness, gloom, lack of energy, anhedonia and often 
rumination about things from the past. These symptoms are according to the dimensional 
approach considered on a continuous scale from being absent to a maximum intensity. In 
contrast, the categorical approach views anxiety and depression as discrete 
psychopathological entities, or disorders. Such disorders are classified as being present or not 
according to a threshold for specific diagnostic criteria (Bjelland, 2004). In the present study, 
the diagnoses are based on categorical diagnoses based on DSM-IV, most commonly used in 
clinical research. 
1.3.1. Unipolar Major Depression (MDD)
We’ve all felt “sad” or “blue” at one time or another. Rare bouts of depression that last only a 
few days are usually not a problem for most people. But, clinical depression, characterized as 
a mental disorder – the type that people seek help for - is a different story. Hence, the general 
term depression often refers to Unipolar Major Depression (MDD) that is a disabling 
condition which may seriously affect and deteriorate a persons daily functioning, family, 
friends, work or school, sleep, eating and health status in general (Austin et al., 2001; McCall 
& Dunn, 2003).
The DSM-IV uses the term “major depressive disorder” to classify and diagnose clinical 
depression. Major depressive episodes are the hallmark features of this type of depression. 
These episodes are often characterized by clinicians as extreme symptoms that interfere with 
daily functioning and may include low mood, which may interfere with all aspects of life,
inability to experience pleasure or joy in activities that they formerly liked. Rumination is the 
preoccupation with thoughts and feelings of worthlessness, strong guilt and regret, 
helplessness, hopelessness and self-loathing and is thought of as one major factor that is 
believed to sustain and maintain the depressive episode. Other symptoms of MDD include 
poor concentration and memory, patients often complain about “falling out of conversations”
and having dependence of checklists to be able to remember appointments, daily chores or 
8activities than they formerly did not need. These cognitive impairments cause a fall in daily 
functioning compared to premorbid level.
In order to fulfill the DSM-IV criteria for MDD, patients must exhibit at least five of the nine 
following symptoms during the same two week period, representing a change from previous 
functioning. At least one of the symptoms must be either (1) depressed mood most of the day, 
nearly every day, or (2) markedly diminished interest or pleasure in all, or almost all, 
activities most of the day, nearly every day. This mood must represent a change from the 
person's normal mood; social, occupational, educational or other important functioning must 
also be negatively impaired by the change in mood.
This disorder is further characterized by the presence of the majority of these symptoms: 
 Depressed mood most of the day, nearly every day, as indicated by either subjective 
report (e.g., feels sad or empty) or observation made by others (e.g., appears tearful). 
(In children and adolescents, this may be characterized as an irritable mood.)
 Markedly diminished interest or pleasure in all, or almost all, activities most of the 
day, nearly every day
 Significant weight loss when not dieting or weight gain (e.g., a change of more than   
5% of body weight in a month), or decrease or increase in appetite nearly every day
 Insomnia or hypersomnia nearly every day
 Psychomotor agitation or retardation nearly every day
 Fatigue or loss of energy nearly every day
 Feelings of worthlessness or excessive or inappropriate guilt nearly every day
 Diminished ability to think or concentrate, or indecisiveness, nearly every day
 Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without 
a specific plan, or a suicide attempt or a specific plan for committing suicide.
Depressed mood caused by substances (drugs, alcohol, and medications) is not considered 
MDD, nor is one which is caused by a general medical condition. MDD cannot be diagnosed 
if a person has a history of manic, hypomanic, or mixed episodes (e.g., a bipolar disorder) or 
if the depressed mood is better accounted for by schizoaffective disorder and is not 
superimposed on schizophrenia, schizophreniform, a delusional or psychotic disorder. 
To qualify for recurrent MDD, the patients must have had a minimum of two depressive 
episodes with an interval of at least two consecutive months where the criteria for MDD are
not fulfilled.
9Cognitive functioning, which is also included in the diagnostic criteria of MDD, is the main 
focus of this study. The interaction between emotion and cognition is an important question 
from both a theoretical and a practical viewpoint. Mood congruent memory is a memory bias 
in which information with affective connotations is better remembered if it is congruent with 
the individual’s mood during retrieval as compared with material that is incongruent with
current mood (Bower, 1981). The mood congruency phenomenon is well established and has 
sparked a wealth of research into the effects of mood changes and emotional disorders on 
cognitive/neuropsychological functioning in general (Rogers et al., 2004). However, cognitive 
impairments are not present in all subjects with MDD. Why some individuals are impaired 
and some perform in the normal range, is not clear (Egeland et al., 2005).
MDD is polythetic, meaning that meeting criteria for the disorder is possible via more than 
one pattern of the diagnostic symptoms. As operationalized by DSM-IV for a diagnosis of 
MDD, 5 out of 9 symptoms with one of those being either depressed mood or irritability, or 
anhedonia, plus a diverse set of potential depressive symptoms, raises the question of the 
heterogeneity of depressive symptoms profiles and the possible different manifestations with 
comorbid anxiety disorders (Small et al., 2008), and specifically regarding associated 
cognitive impairments.
In addition, the variety of factors that may contribute to variability in symptom presentation 
may also influence the manifestation of cognitive impairments in depressive disorders, this 
can include: levels of severity, subtypes, number of episodes, co-morbidity and 
the range of negative affective traits and states have not been properly addressed or controlled 
for in the majority of studies in the field, and may explain the lack of consistently observed 
across studies. (e. g. Austin et al., 2001; Purcell et al., 1997; Porter et al., 2003;
Mohanty et al., 2002, Rogers et al., 2004; Levin et al., 2007).
1.3.2. Anxiety (A)
Anxiety is a natural human response and a necessary and beneficial response and warning 
adaptation in humans. For example, dangerous situations trigger anxiety in the form of a 
fight-or-flight stress response that is necessary for our survival. Or, sometimes anxiety gives 
us the necessary push we need to get things done
But anxiety may become a pathologic disorder when it’s excessive, uncontrollable, requires 
no specific external stimulus and manifests in a range of affective and physical symptoms in 
addition to more behavioural and cognitive changes (Rowney et al., 2010).
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The symptoms may lead to an anxiety disorder if they are: severe or last a long time, out of 
proportion to the situation at hand and/or causing extreme behaviours (i.e., avoidance) to 
reduce the anxiety. Phobias are derived from the Greek word fobos that means fear or fright. 
A phobia is physical reactions on fear, that comes automatic and that is not controlled by will. 
Phobias are characterized as an anxiety disorder. It should also be noted that anxiety can be a 
central aspect of depression, causing an anxious or agitated depression. 
The primary anxiety disorders generally develop before the age of 30, are more common in 
women than men, and are associated with a family history of anxiety and depression (APA, 
1994; Kessler et al., 1994).
DSM-IV categorize anxiety disorders into: generalized anxiety disorder (GAD), panic 
disorder (PD) with and without agoraphobia, agoraphobia without a history of panic disorder,
phobic disorders (social anxiety and specific), obsessive-compulsive disorder (OCD),  
posttraumatic stress disorder (PTSD), acute stress disorder, substance induced anxiety 
disorder or due to medical conditions and anxiety disorder not otherwise specified (NOS).
1.3.3. Co-morbid MDD and A (MDDA)
The co-occurrence, or comorbidity, of two or more disorders is relatively common in 
psychiatry some critics claim that co-morbidity is simply an artefact of splitting nosological
entities into separate classes. Hence, two disorders that have some common diagnostic criteria
are more prone to co-occur, which is called diagnostic comorbidity (Kaplan & Feinstein, 
1974).
Co-morbidity between two of the most common psychiatric disorders, namely depression and 
anxiety, has several consequences including increased symptom severity (Sherburne & Wells, 
1997), impaired treatment response to antidepressive medication (Brown et al., 1996), 
impaired recovery rate from depression, increased time to recovery, decreased time to relapse 
(Hayden & Klein, 2001; Coryell et al., 1992), as well as increased risk for suicide (Angst, 
1993). Anxiety can also potentially confound or contribute to neuropsychological 
impairments or anatomic changes in depressed individuals (Cameron et al., 2004; Leonardo et 
al., 2006).
Although it is well known that anxiety and depression are highly correlated (Mineka et al., 
1998), and this is of high clinical significance, studies addressing the co-occurrence of MDD 
and A are very few, and the majority of studies of either MDD or A have up to date not 
accounted for the co-occurrence of the other. As a result of this, there is no broad consensus
whether the findings are due to the depression or the anxiety component or both.
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In addition, both MDD and A are syndromes and hence heterogeneous including different 
subtypes, and the research have often focused on one anxiety subtype or a merge of different 
depressive and anxiety disorders without differentiating between possible subtypes or 
combinations. 
However, there is still controversy how one should characterize the constructs of MDD and 
A, and whether they should be considered as categorical diagnoses or phenomena on a 
continuum. Hence, studies addressing comorbidity have almost exclusively applied a 
categorical approach (Maser & Patterson, 2002), therefore due to the focus of this study and 
from a clinical point of view, it is necessary to diagnostically identify patients with MDD 
and/or A in order to obtain reliability of the samples, validity of results and to provide the 
optimal treatment in clinical settings and health care services.
1.4. Symptom severity
In this study we have included and controlled for  measures of depressive and anxiety 
symptom severity in addition to the primary focus; the diagnoses (syndrome) according to 
DSM-IV criteria. Symptom severity measured with the self-report questionnaires: the Beck 
Depression Inventory (BDI-II; Beck, Steer, & Brown, 1961) and the Beck Anxiety Inventory 
(BAI; Beck & Steer, 1988), may give additional information regarding the present level of 
symptoms the current day of testing and explore whether depressive and/or anxiety symptom 
severity may account for some of the variance. 
MDD with more pronounced depressive symptoms have also shown associations with more 
prominent cognitive dysfunction (Grant et al. 2001; Albus et al., 1996; Weiland-Fiedler et al., 
2004).  In a study Channon and Green (1999) reported executive function deficits in 
dysphoric undergraduate students relative to those with normal mood as defined by Beck 
Depression Inventory (BDI). This might suggest that cognitive deficits may be be associated 
with depressed mood or symptoms rather than clinical syndrome depression. Others have 
found no relation between self-reported depression and anxiety (BDI/STAI) and executive 
measures (see Smitherman et al., 2007).
A PET study by Osuch et al. (2000) found that depressive symptom severity correlated with 
increasing activation in the right dorsal lateral and bilateral medial frontal cortex as well as 
the right anterior cingulated gyrus. In contrast, increasing anxiety symptoms correlated with 
greater activation in the left anterior cingulate and right parahippocampal gyrus. This may 
imply that co-morbid depressive and anxiety symptoms may exert neurobehavioral effects 
that differ from those observed in one alone and may be attributable to co-morbid MDD and 
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A disorders. But the discussion about whether cognitive dysfunctions in depression and 
anxiety represent symptom or syndrome factors or an interaction of both with situational 
stress as a mediating factor is still ongoing (Eysenck & Calvo, 1992; Chong, 2003; Murray & 
Janelle, 2003).
1.5. Recurrent depressive episodes
The majority of patients with MDD will experience recurrent episodes of depression, and it is 
therefore vital to achieve more information to the association between number of recurrent 
depressive episodes and neuropsychological function. Depression has a high recurrence rate: 
around 80% of depressed patients will experience more than one depressive episode over their 
lifetime (Kessler et al., 1997; Vanderhasselt et al., 2009), and research reveals that patients 
become more vulnerable after each depressive episode, with an increased chance for the onset 
and maintenance of a depressive episode (Monroe & Harkness, 2005; Vanderhasselt et al., 
2009).
There are findings suggesting that cognitive impairments are prevalent in individuals with 
recurrent depression, and not in persons that experience their first episode (Basso &
Bornstein, 1999b; Fossati et al., 2004). However, it is important to notice that findings differ
across studies.
There are research findings where number of earlier depressive episodes show a cumulative 
effect on cognitive control dysfunctions in MDD (Vanderhasselt & De Raedt, 2009; Kessing, 
1998), and hence support the theories of recurrent episodes leaving a “scar” that affects 
cognition and that patients become more vulnerable after each depressive episode with an 
increased chance for the onset and maintenance of a depressive episode (e.g. . Monroe & 
Harkness, 2005). Others have found no association between number of episodes and 
executive impairment in MDD (Grant et al., 2001; Reisches & Neu, 2000; Lampe et al., 
2004). Post (1992) proposed that fundamental neurochemical changes occur as a function of 
successive depressive episodes. As a consequence of these changes cerebral dysfunction 
increases with each episode, this may in turn decrease the threshold for onset of subsequent 
depressive episodes. In a research report, Paelecke-Habermann et al. (2005) state that the 
database regarding the relationship between cognitive impairments and number of episodes is 
inconsistent and not well understood. Additional risk factors for recurrence that have been 
suggested other than previous depressive episodes are: female gender, length of first episode, 
loss events, genetic vulnerability, psychosocial factors, previous hospitalization, late-onset 
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depression, family history, to never have been married, and age of onset first depressive 
episode (Mueller et al, 1999; Angst, 1999; Burcusa & Iacono, 2007).
In sum, more research that take into account number of earlier depressive episodes when 
Studying cognitive functions in MDD are needed to expand the knowledge and understanding 
of the possible cumulative effects of recurring depressive episodes on cognition.
1.6. Age of onset 
One of several clinical features that may contribute as a risk factor for recurrence of 
depression is age of onset for first depressive episode (Burcusa & Iacono, 2007). Several 
studies have examined the role that age of onset for first episode relates to later recurrence of 
depression, but these studies have yielded conflicting results, from reports on relation between 
early onset greater and greater risk for recurrence (Gilman et al., 2003; Klein et al., 1999; 
O’Leary & Lee, 1996), to no findings of a relationship between age of onset and subsequent 
recurrent episodes (Birmaher et al., 2004; Kovacs et al., 2003). The studies that did not find a 
significant relationship are similar in that they did not control for number of prior depressive 
episodes, but looked at risk for recurrence in those with a history of any number of episodes. 
While age at onset and number of depressive episodes are moderately correlated, they are not 
completely synonymous, and should both be addressed (Burcusa & Iacono, 2007).
Regarding age of onset of depression and relation to cognitive deficits, studies have found 
that younger onset of the disorder predict poorer performance on tasks demanding executive 
functions (Castaneda et al., 2008; Castaneda et al., 2010; Grant et al., 2001).
In sum, studies involving simultaneous assessment of onset age and number of recurrent 
episodes regarding effect on e.g. cognitive functioning in affective disorder patients are 
needed in order to gain information of different factors affecting clinical diagnoses and 
subtypes, formulation of prognosis, prediction of treatment requirements and to add 
information about phenotyping of mood disorders for the purpose of research (Tondo et al., 
2010).
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1.7. Neuropsychological impairments 
1.7.1. MDD
A number of studies indicate cognitive impairments in mood disorders (Veiel, 1997; Austin et 
al., 2001; Landrø et al., 2001; Rogers et al., 2004, Levin et al., 2007), but a limited range of 
neuropsychological functions have typically been assessed in each individual study and the 
research field in general has, up to date, been characterized by contradictory, mixed patterns
of findings and heterogeneous test performance. 
However, there is a relative consensus in the research field regarding deficits in depression 
compared to healthy controls in broad domains of functioning regarding executive functions
(Austin et al., 2001; Degl’Innocenti et al., 1998; Porter et al., 2003; Elliot et al., 1996; Fossati 
et al., 1999; Grant et al., 2001; Fossati et al., 2002; Kaiser et al., 2003;  Gualtieri et al., 2006,
Channon & Green , 1996; Harvey et al., 2004), psychomotor speed (Austin et al., 1992;
Degl’Innocenti et al., 1998; Tsourtos et al., 2002; Gualtieri et al, 2006), attention (Landrø et 
al., 2001; Porter et al., 2003; Sweeney et al., 2000), and memory functions (Austin et al., 
1992; Elliot et al., 1996; Landrø et al., 2001; Rose et al., 2003; Veiel et al., 1997).
The most frequent explanation that interactions between affect and cognition in mood 
disorders have yielded divergent results across studies, relates to between-subjects 
differences, namely: heterogeneity of patient samples, age differences, presence of psychosis, 
medication, psychomotor retardation, length and severity of illness, number of recurrent 
episodes and co-morbidities (Pardo et al., 2006). Another reason may be that the research 
field consists of the use of multidimensional definitions and operationalizations into tasks to 
assess cognitive functions or domains that often include several other subfunctions (“the task 
impurity problem”) (Philips, 1997). 
Aalthough cognitive dysfunction is a feature in depression, the nature and specificity remains 
somewhat unclear. Therefore, to use models and tasks that separate the more underlying 
functions and related networks involved in the cognitive domains may enhance greater
specificity, and better support for inferences from the task performance, in which cognitive 
functions that are affected and which are not.
In sum, the contradictory research field regarding neuropsychological functions in MDD may 
mainly be due to seldom accounted for between-subject factors, especially co-morbid anxiety 
in addition to the operationalizations of cognitive domains into tests that may measure 
multiple cognitive subfunctions.
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1.7.2. Anxiety
The impact of anxiety on cognitive functioning is much less explored than depression.
Regarding anxiety disorders in general there are few studies and a mixed pattern of findings,
from no deficits (Gladsjo et al., 1998; Purcell et al., 1998) to deficits on a range of different 
cognitive functions, such as memory and learning (Constant et al., 2005; Lucas et al., 1991; 
Asmundson et al, 1994;  Boldrini et al., 2005), executive functions (Cohen et al., 1996; Olley 
et al., 2007; Purcell et al., 1998), and impaired attentional control to threat related stimuli
(Broadbent et al., 1986; Bishop et al., 2004). Anxiety disorders have also been associated with 
heightened distractibility, poor concentration and increased responsivity to potential threat 
(Bishop et al., 2004).
The inconsistent and mixed findings in the research field may likely be the result of 
methodological differences between studies regarding selection of participants, that is, few 
studies differentiate between the different anxiety subtypes, and traditionally focus on one 
subtype or they mix different anxiety disorders into an overarching diagnostic disorder.
More importantly, co-morbid depression is seldom accounted for, and the often contradictory 
findings may be related to whether cognitive dysfunctions in anxiety may be accounted for by
co-morbid depression or by the anxiety disorder independent of depression.
1.7.3. MDDA
There are extensive co-morbidity between MDD and other affective disorders, especially 
anxiety disorders (A), in regards to both phenomenological features and neuropsychological
functioning. In individuals with depression or an anxiety disorder, co-morbidity with the other 
disorder is associated with pronounced cognitive dysfunction, and anxiety can potentially 
confound or contribute to neuropsychological impairments or anatomic changes in depressed 
individuals (Cameron et al., 2004; Leonardo et al., 2006; Castaneda et al., 2008). 
Despite the high co-morbidity rate, and that co-morbid anxiety is an important factor that 
potentially can contribute to inconsistencies between studies and should be addressed 
accordingly, up to date research have paid little attention to and hence provided very little 
information regarding the effect of co-morbid anxiety on cognitive dysfunctions in MDD.
Studies on cognitive impairments in depression have often inadequately controlled for or not 
taken into account co-morbid anxiety as a confounding variable, and may as a result, explain 
some of the contradictory results in the research field (Castaneda et al., 2008).
Lilienfeld (2007) points out challenges when dealing with co-morbid MDD and anxiety. The 
fact that co-morbidity is more often the rule than the exception gives rise to difficulties 
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regarding specificity. To be able to establish the specificity versus generalizability of 
abnormalities associated with MDD and MDDA in this study, the need to compare these 
clinical groups in addition to a healthy control groups is essential.
Rogers et al. (2004) highlight in a review the critical importance that very few studies 
measure and report co-morbid anxiety in their samples, even if the presence of co-morbid 
anxiety have been shown in some cases to account for a considerable portion of the cross-
study variability in reported executive function impairments in individuals with depression.
The very few studies on MDD with co-morbid anxiety disorder have also traditionally 
focused on one anxiety subgroup.
In a review of the existing literature on cognitive impairments in depression and anxiety 
among young adults, Castaneda et al. (2008) concluded that cognitive impairments are 
common in both anxiety and depression, whereas executive dysfunctions were associated with 
depression. The neuropsychological profile in anxiety; although their nature remains partly 
unclear, seem to be depend on anxiety subtype. Castaneda et al. (2008) explain the conflicting 
results in the literature by the heterogeneity found within study participants. This review, 
however, do not focus on MDD as primary diagnosis with co-morbid anxiety disorders, but 
take into account research on a wealth of depressive and anxiety disorders compared to 
healthy control groups.
Two studies that assessed co-morbidity, used anxiety as the primary diagnosis and addresses
panic disorders (PD), MDD, and PD with co-morbid MDD. They did not, however, measure
neuropsychological functions, but found the co-morbid PD with MDD having more severe
psychopathology and symptoms of somatic preoccupation and social-evaluative fear than the 
two pure clinical groups (Andrade et al., 1994; Woody et al., 1998). These results suggest that 
co-morbid anxiety may hold additional maladaptive beliefs beyond specific cognitions 
typically associated with each disorder alone. Other studies that use anxiety as primary 
diagnosis, but include neuropsychological measures, focus on one anxiety subtype. Kaplan et 
al. (2006) compared patients with PD,  PD with co-morbid MDD and matched healthy 
controls (HC) on subtests measuring attention, memory, psychomotor speed, executive 
functioning, decision-making and affective processing. The co-morbid group demonstrated 
deficits in visual discrimination and working memory compared to HC, in addition to an 
attentional bias towards negatively valenced stimuli. However, this study did not compare the 
clinical groups directly. Graver et al. (2006) studied the influence of stress on 
neuropsychological functioning and found no significant differences between groups with
social phobia (SP), SP with co-morbid MDD and HC on baseline conditions without an 
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exogenous stressor. Basso et al. (2001) examined the relative impact of depression on 
executive function deficits and sensory-motor functions in OCD on a broad battery of 
neuropsychological tests. The results suggested that abnormalities involving executive 
function in OCD are linked to concurrent depressive severity, and less to OCD. However, the 
limitations of this study consists of patient data collected retrospectively and addressed co-
morbid depressive symptoms and not diagnostic MDD (Basso et al., 2001).
Studies that address MDD as the primary diagnosis often use samples of mixed psychiatric 
axis I diagnoses and medical co-morbid disorders. One example is Castaneda et al. (2010) that 
conducted a study on a population-based sample of patients with a history of MDD compared 
to a healthy control group by examining the effects of co-morbidity Axis I disorders on a 
broad range of neuropsychological tests. They found that the groups with  MDD and the 
MDD with co-morbid Axis I disorder group did not differ in any of the cognitive measures 
assessed, and conclude that psychiatric co-morbidity may not aggravate cognitive functioning 
among depressed young adults. That the co-morbid group consisted of a mix of anxiety 
disorders, substance abuse, eating disorders and other axis I disorders are limitations of this 
study, in addition only nine out of sixty-nine MDD patients had current MDD.
Contrary to these results, a study that aimed to investigate the association between cognitive 
performance and medical and psychiatric co-morbidity in MDD, Baune et al. (2009)
concluded that the strongest predictor of poor cognitive performance in depression was 
psychiatric co-morbidity. The MDD with co-morbid psychiatric disorders showed decreased 
cognitive performance in visouspatial/constructional and language domain and total score on 
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), but the study 
did not include a healthy control group. Mini Mental State was used as a mean for diagnosis, 
and the depressed sample consisted of both bipolar and unipolar patients in addition to the 
wide range of psychiatric co-morbid disorders, all of which are limitations to address.
DeLuca et al. (2005) studied geriatric patients with MDD, and MDD with comorbid GAD 
and/or PD using measures of symptoms, functional disability and cognitive disability (Mini 
Mental Status Exam (MMSE). MDD and co-morbid GAD or PD were found to be associated 
with greater decline in memory in late life MDD, but the MMSE is a short questionnaire used 
for screening of daily life cognitive functions, and do not measure cognitive functioning with 
the same sensitivity as neuropsychological tests, in addition to the limited generalizability of 
the samples studied.
Other studies have used self-reported depression and anxiety symptoms in mixed psychiatric 
samples and not utilized diagnostic criteria according to DSM-IV. Smitherman et al. (2007)
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evaluated the relation between mood and executive functioning in records from adult 
outpatients and found the correlations between the self-reported depression and anxiety and 
measures of executive functioning to be small and non-significant. Kizilbash et al. (2002) 
studied a large sample of veterans with self-reported depressive-, anxiety and co-morbid 
depressive and anxiety symptoms regarding memory functions, and found that depressive 
symptoms had an adverse effect on immediate recall, anxiety symptoms no effect, but the co-
morbid group showed not only an adverse effect on immediate recall but also effect on
retrieval of newly learned information. They conclude that the presence of co-morbid anxiety 
may, in part, account for the variability of previous research findings regarding the effects of 
depression in memory functioning, but this study did not have a defined diagnosis of
depressive and anxiety disorders.
Airaksinen et al. (2004) studied population-based samples that fulfilled the DSM-IV criteria 
of MDD, dysthymia, mixed anxiety-depressive disorder and minor depression with a healthy 
comparison group on a variety of cognitive tasks. They found that both the MDD and mixed 
anxiety-depression group exhibited significant memory dysfunctions compared to HC. They 
did however not find differences between MDD and the mixed group, but found significant 
differences between the depressive subgroups dysthymia and minor depression compared to 
the two former. They conclude that cognitive impairments vary as a function of depressive 
subgroup.
One of the few studies that address and seek out to explore how co-morbid anxiety 
corresponds with neuropsychological dysfunction in unipolar depression is Basso et al. (2007)
that compared depressed inpatients with and without co-morbid anxiety disorders to a group 
of healthy controls on a brief but broad battery of neuropsychological tests. The results 
showed that both clinical groups showed worse memory functions than controls, but that 
attention, executive dysfunction and psychomotor slowing were specific to the depressed 
group with co-morbid anxiety. The latter group also displayed more impaired scores than both 
“pure” MDD and HC. Basso et al. (2007) concluded that MDD corresponds with significant 
memory impairments regardless of co-morbid anxiety, but the presence of co-morbid anxiety 
displays deficits involving executive functions and psychomotor slowing. The limitations of 
this study are mainly the reliability of patient diagnoses; the data were collected 
retrospectively from available records and these recorded diagnoses lacked a structural 
diagnostic interview and were made by a psychiatrist at the hospital. The patient samples also 
consist entirely of inpatients, and the literature suggests that inpatients are more severely 
impaired than outpatients. The brief neuropsychological battery, do as many studies in the 
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field traditionally have been doing, namely choose tests that tap unitary, general purpose 
executive functions.
In a clinical trial, Herrera-Guzmàn et al. (2009) found no differences between MDD patients 
with or without co-morbid anxiety at baseline on any of the neuropsychological variables 
studied. In line with these findings, Castaneda et al. (2010) also found no significant 
differences between the population-based clinical groups MDD, MDD with co-morbid mixed 
anxiety/substance abuse/eating disorders and other axis I disorders on a range of 
neuropsychological tests. However, the majority of the patients in the MDD group were in 
remission and only a few had current MDD.
In sum, research concerning MDD and A disorders separate, suggest that neuropsychological 
deficits are present in both disorders, but there are few studies that examine their 
simultaneous effect on neuropsychological functioning, and especially address primary MDD 
with co-morbid anxiety disorders. The co-morbid samples often consist of mixed axis I 
disorders and there are few that seek out to explore neuropsychological functions. The few 
studies that have systematically examined the impact of MDD with co-morbid A on
neuropsychological functions, have yielded contradictory results (i.e. Basso et al., 2007; 
Castaneda, 2010; Herrera-Guzmàn et al., 2009), and the conclusions must be regarded as 
tentative due to several inconsistencies between studies. Methodological factors that may 
account for some of the inconsistencies are; variability in clinical subtypes used in each study, 
small sample sizes, low reliability regarding diagnostic screening, difference of in- and 
outpatient samples, methodological heterogeneity regarding use of different and general tests 
to operationalize cognitive functions, and not taking into account the diversity of their 
subfunctions.
There were also performed more formal searches to identify research in the field. There were 
conducted electronically searches using PubMed, PcyInfo(Ovid), ISI Web of knowledge (all 
databases, all years) to identify research articles that focus on neuropsychological measures in 
MDD with co-morbid anxiety disorders. Different forms and combinations of the following 
search terms were used: depression, anxiety, panic disorder, phobia, generalized anxiety 
disorder, post-traumatic stress disorder, obsessive-compulsive disorder, social phobia/anxiety,
agoraphobia, co-morbid depression/ anxiety, neuropsychology, cognitive 
deficits/dysfunctions/impairment, executive functions, cognitive control functions, memory, 
working memory, attention. In addition, reference lists were screened in order to include 
further relevant studies. See overview in table below.
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1.8. Definitions and cognitive models
The three papers have dealt with different cognitive domains such as executive control 
functions, attention and memory, the cognitive domains that are the most commonly observed 
deficits in MDD and A. There are unclear boundaries and relations between the concept 
executive functions and concepts such as attention and memory, both in regards to cognitive 
models and the use of overlapping or identical neuropsychological tests to measure the same 
functions, this mostly due to their complexity as cognitive domains comprising of different 
subfunctions. In our study, we separated the areas in the analyses to avoid the emergence of 
cognitive profiles that would cloud the main focus, that is, differences between MDD and 
MDDA in these specific cognitive areas. Operationalisations of the cognitive areas are based 
on theory and models, in addition to empirical traditions of the neuropsychological tests used 
to measure them.
1.8.1. Attention
Attention have in the literature been described as both a more higher order or executive 
attentional system of sustained focus and control of cognitive resources on information while 
filtering or ignoring extraenous information, to be subdivided into basic subfunctions and
seen as precursor to other cognitive functions (Lezak, 2004; Knudsen, 2007).
At a basic level, Fan et al. (2005) and Posner et al. (1990) fractionate three independent and 
separable aspects of attention, namely: Alerting (when), Orienting (where/spatial) and 
executive control (conflict or congruent/incongruent). These three aspects are subserved by
three distinct and relatively independent neural networks (Fan et al., 2002).
In a review, Knudsen (2007) describes a general model which identifies four core processes 
of attention, with working memory at the centre, including selection processes that determines 
information access to WM, in addition to both top-down sensitivity control, higher cognitive 
processes that can regulate information processing to more bottom-up saliency filters of 
stimuli. Knudsen (2007) proposes a conceptual framework for attention that reflects the 
combined contributions of the different processes involved, from higher order to lower level 
processes and their potential overlapping. In our study, we wanted to address both the higher 
level and basic level attentional functions in order to specify, and perhaps identify key 
functional components in which attentional impairments manifest in MDD and MDDA.
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1.8.2. Memory 
In our study we also wanted to address different memory functions in order to identify the 
components of memory in which MDD and MDDA show impairments.
Memory is often considered a higher-level cognitive function, and there is consensus that it is 
not a unitary concept, but involves several different processes. Cognitive models often make 
distinctions between short-term memory (STM), working memory (WM) and long-term 
memory (LTM) (Gazzaniga, 2008). 
Theoretical frameworks on working memory (Baddeley, 1986; Norman & Shallice, 1986)
have provided cognitive models that are still highly present in the field. Baddeley & Hitch 
(1974) state that the WM consists of the attentional system, the Central Executive (CE) and
two slave systems/storage buffers assumed to be rather independent. They propose WM and 
the CE as an attention system related to Norman and Shallice’s (1986) supervisory attention 
system (SAS), that describes the control of action and attention attributed to the central 
executive that regulates the active portion of memory. Similarly, Engle et al (2002) view WM 
capacity as fundamentally related to domain general executive attention or the central 
executive aspect of WM. Engle (2002) further states that WM capacity is about differences in 
ability to control attention to maintain information in an active, quickly retrievable state.
Domain-specific skills or expertise, like reading comprehension and arithmetic, cannot 
account for why WM capacity tasks correlate with performance on higher-order tasks, and 
therefore WM capacity or CE is, according to Engle (2002) and Kane & Engle (2000); an 
ability to control attention and dealing with the effects of proactive interference rather than 
memory storage.
1.8.3. Executive functions
Up to date there have been no broad consensus regarding the definition and operationalization 
of executive functions (EF). In addition, the differentiation between EF and concepts like 
attention and memory has also been unclear. This may be due to several reasons: EF is 
considered a higher-order top down processing involving many subfunctions, and therefore 
operate on and influence many lower level cognitive functions such as attention and memory 
functions (Lezak, 2004). Any deficits in executive function could then have a major impact on 
performance of normal daily routines, so their identification could be crucial for the 
development of therapies to support everyday function and to gain a better understanding of 
the nature of mood disorders (Taylor-Tavares et al., 2007).
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Executive control functions refer to mental functions that have the overarching control and 
modulation of cognitive processes, and therefore they have traditionally been considered a 
unitary, general purpose ability that can be measured with a single complex task (i.e. WCST, 
Stroop, TMT-B) (Lezak, 2004). Executive tasks have therefore tended to suffer from 
relatively low internal and/or test-retest reliability (Denckla, 1996; Rabbitt, 1997; Miyake et 
al., 2000), and the widely used and accepted tests to measure EF have based their construct 
validity on loose criterion as “sensitive to frontal lobe damage”. This limits their usefulness in 
identifying specificity in impairment, and to seize out the more basic underlying executive 
control functions hypothesized to be subserved by the prefrontal cortex (PFC), and especially 
the anterior cingulate cortex (ACC) and its networks (Colette et al., 2002; Bar-Haim et al., 
2007; Fan et al. 2002; Bush et al., 2000; Thomas & Elliot, 2009; Pizzagali et al., 2001). 
The tests traditionally used to measure EF have therefore been too broad, and “executive 
tests” often used in neuropsychological studies involve many functions, making it difficult to 
seize out the primary functional deficit associated with any one complex task, that is, which 
cognitive functions that are measured, hence “the task impurity problem (Burgess, 1997; 
Philips, 1997; Friedman et al., 2009). Different “executive tests” have also shown to typically 
correlate low with each other. It is therefore reasonable to assume that these tests partly 
measure different functions/processes from higher-level to more basic functions, making it 
difficult to cease out the primary functional deficit. Evidence from neuropsychological 
research indicates, however, that executive control more accurately can be characterized as a 
collection of related but separable abilities (Baddeley, 1986; Friedman et al., 2006; Friedman 
et al., 2009).
Since the consensus about EF is difficult, the focus may be on the way EF have been 
operationalized and measured. To increase the ecological validity, the need for better tests 
and models to capture and operationalize all aspects of  EF will be crucial in future research.
Even if there have been no clear consensus on how to best define or conceptualize executive 
functions, recent neuropsychological research suggests that executive functions are 
multifaceted and that different types of executive functions are correlated but separable 
(Friedman et al., 2006). These three executive functions (inhibiting dominant responses, 
updating working memory representations, and shifting between task sets) have dominated 
recent executive control function research, and have been confirmed in studies by Miyake et 
al. (2000) and Friedman et al. (2009).
Based on a firm theoretically driven model, Miyake et al. (2000) used latent variable analysis
in a study to determine to what extent different executive processes can be considered to be 
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unitary (in the sense that they are reflections of the same underlying mechanism or ability) or 
non-unitary. They focused on the following three basic executive functions: (1) shifting 
between tasks or mental sets, (2) inhibition of dominant or prepotent responses, and (3) 
updating and monitoring of the contents of working memory. Confirmatory factor analysis 
indicated that these three executive processes, although moderately correlated with one 
another, are clearly separable. Moreover, structural equation modeling suggested that the 
three functions contribute differentially to performance on complex executive tasks. These 
results suggest that it is important to recognize both the unity and the diversity of executive 
functions (Miyake et al., 2000).
Neuropsychological studies of mood disorders based on an empirically based model of basic 
executive control functions are lacking, and therefore we wanted to address this in our study.
1.9. Explanatory frameworks
Two frameworks that have been trying to explain the impact of affect on cognitive deficits are 
the Effort-hypothesis/Cognitive load theory and the Cognitive Speed hypothesis.
Cognitive load theory or the Effortful-processing theory is a theoretical position trying to 
explain impairments in depression where patients show more difficulties on tasks that demand 
cognitive effort as opposed to automatic and over learned material, that is, higher level 
effortful tasks versus more basic lower level tasks. Effortful information processing requires 
considerable cognitive resources and may interfere with other cognitive activities that also 
require cognitive capacity. One example is the well-known “Stroop-effect” that consists of 
four trials where the first two are automatic and the second two require mental effort. 
Cognitive load have also broadly been referred to cognitive load related to the executive 
control of WM or, at a more basic level, the load on working memory in a task.
Negative mood and rumination require generally more attention than neutral and positive 
stimuli (Dolcos & McCarthy, 2006; Van Dillen & Koole, 2007). And as in major depression, 
strong negative stimuli may trigger more mood-congruent processing and thus employ more 
WM capacity. Eysenck & Calvo (1992) have suggested that the impact anxiety have on 
cognitive load, is associated with depletion of central executive resources (restrictions in WM 
capacity) in accordance with the original model of Baddeley & Hitch (1974). Due to the task-
irrelevant worrisome thoughts, anxiety is though to deply resources otherwise available to 
support WM, or more specific; central executive resources. However, this does not explain all 
the findings in the field. Others explain anxiety as a heightened attention to threat and 
therefore more load in visuospatial attention (Shackman et al., 2006).
25
The Cognitive Speed-hypothesis proposes that ccognitive dysfunction in depression are
caused by cognitive slowness (i.e. reduction in mental speed or cognitive speed processing)
that are general, task-independent non-specific slowing of processing speed, and therefore 
may  negatively affect higher cognitive functioning (Den Hartog et al., 2003; Egeland et al., 
2003). Several studies have provided support for this speed hypothesis of cognitive deficits in 
both depressed patients and patients with co-morbid anxiety (e.g. Zakzanis et al., 1998; Nebes 
et  al., 2000, Castaneda et al., 2008). But when problems of higher cognitive processing are
not accompanied by speed problems, this hypothesis appears to be invalid (Den Hartog et al., 
2003). Other studies have shown contradictory findings, and argue that cognitive deficits are 
not associated with non-specific changes in cognitive performance but to specific processes, 
such as attentional processes (Erickson et al., 2005). To our knowledge, a few studies (Dutke 
and Stöber, 2001) have found that anxiety affect psychomotor acceleration, whereas 
numerous theories states that the presence of anxiety (specifically OCD) yields slower 
processing due to an obsessive or ruminative approach to testing (Basso et al., 2007).
In light of these frameworks, it may be hypothesized that both MDD and A, and thus MDDA, 
may affect cognitive load and /or psychomotor speed.
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2.0. AIMS OF THE STUDY
The overall aim of the study was to investigate neuropsychological functions in persons with 
MDD compared to MDDA and HC, by assessing neuropsychological performance in 
executive control functions, attentional functions and memory functions.
Other facets examined in the papers were the effects of potentially confounding factors such 
as a) number of depressive episodes, b) anxiety and depressive symptom severity, and b) age 
of onset for the first depressive episode on neuropsychological functioning.
2.1. Paper I
The aim of the first paper was to investigate different levels of attentional networks for 
neutral stimuli processing in patients with MDD and MDDA compared to HC. 
2.2. Paper II
The aim of the second paper was to examine the central executive control aspects of verbal 
working memory (WM) functions, as well as verbal learning and long-term storage functions
in MDD and MDDA compared to HC.
2.3. Paper III
The aim the third paper was to systematically investigate basic components of executive 
cognitive control functions according to Miyake’s model, in patients with MDD and MDDA
compared to a HC group. 
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3.0. METHODS
3.1. Design
The papers included in this thesis are based on between-subjects designs.
3.2. Sample
The study was approved by the Regional Committee for Medical Research Ethics, Norwegian 
Social Science Data Services (NSD) and adhered to the Helsinki Convention. Written 
informed consent was obtained from all participants. 
3.2.1. Participants
The three studies included in this thesis are based on the same samples. The 
neuropsychological data collected were divided into three studies according to the different 
neuropsychological functional areas, from basic attention, via memory to executive control 
functions. Paper III includes all participants, but due to technical and/or administrative 
problems data are lacking for participants in Paper II: 1 HC. Paper I lacks 4 MDD and 3 HC 
on the ANT, and 1 HC on Stroop.
The distribution of the anxiety subtypes in the MDDA group was: General Anxiety Disorder 
(GAD) = 3, Social phobia= 13, Obsessive-Compulsive Disorder (OCD) =4, Posttraumatic 
Stress Disorder (PTSD) = 2, Panic with agoraphobia= 6, Panic without agoraphobia= 4,
Specific phobia= 3, Anxiety Not Otherwise Specified (NOS) = 2. Fourteen participants had 
one anxiety diagnosis, and ten participants had two or three anxiety disorders. 
3.2.2. Inclusion criteria
General inclusion criteria were age between 18-65 years, to speak fluent Norwegian and no 
medication taken other than Selective Serotonin Reuptake Inhibitors or Serotonin-
Norepinephrine Reuptake Inhibitors (SSRI/SNRI). Prior to testing the patients were required 
to be medication-fasting the day of testing. 
3.2.3. Exclusion criteria
General exclusion criteria were a history of neurological disorders (i.e. Adhd, Tourettes,
unconsciousness for more than 30 minutes), bipolar disorder, psychosis, present drug and/or 
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alcohol-abuse. 	
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subtest Similarities. 
3.3. Clinical evaluation
3.3.1. Diagnostics SCID-I/II
Clinical and diagnostic assessment was made in accordance with Structured Clinical 
Interviews for DSM-IV criteria (APA, 1994). Both SCID-I and SCID-II were utilized by 
trained professional clinical psychologists. All assessment was audio-taped with consent and 
with instruction to the participant of not using names or other recognizable issues.
In addition, the rating was later blindly repeated by means of the original audio-taped 
interviews by an external experienced clinical psychologist who was unaware as to whether 
the participants where MDD or MDDA (validated by one of the co-authors; TCS). 
3.3.2. Symptom severity
The Beck Depression Inventory (BDI-II; Beck, Steer, & Brown, 1961) and The Beck Anxiety 
Inventory (BAI; Beck & Steer, 1988) were filled out by the participants at the time of testing,
to measure severity of depression and anxiety symptoms. 
3.3.3. General functioning
General level of functioning were screened using Global Assessment of Functions Scale for 
symptom and function, split version (GAF-S and GAF-F; DMS-IV; APA, 2000). The scale is 
presented and described in the DSM-IV. The split version of GAF is divided in one version 
for functioning and one for symptomatology.
3.3.4. Demographics
Education level was classified by means of The International Standard Classification of 
Education (ISCED; UNESCO, 1997) in addition to years of education.
General medical and psychiatric background, demographic information, number of past 
episodes of recurrent major depression, age of onset and family medical and psychiatric 
history were screened using a semi-structured interview developed by P. Lyche (2006) based 
on the Diagnostic Interview for Genetic Studies (DIGS; Nurnberger et al., 1994) and a semi-
structured screening-instrument for recurrent depressive episodes and length of episodes 
developed by Biringer (2005) (See Appendix 1).
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3.4. General cognitive measures
General cognitive functioning was estimated from the mean of two subtests from the 
Wechsler Adult Intelligence Scale Third edition (WAIS-III); Picture Completion (PC) and 
Similarities (SI) (Wechsler, 1999). The two subtests were thought to represent the verbal and 
performance aspect of general cognitive functioning and are highly correlated with their 
respective indexes that is Perceptual organization index (POI) and Verbal comprehension 
index (VCI), whereas POI and VCI together are, according to Egeland et al. (2009) 
considered an adequate alternative measure of general cognitive functioning. We are aware 
that most studies rely on other subtests like Verbal Comprehension as a resistant measure 
when it comes to measuring premorbid intellectual functioning in i.e. brain injured patients. 
But our rationale was that the dyad VIQ (Verbal Comprehension) and PIQ (Perceptual 
organization), that represent the most and second most reliable index, were adequate when we 
in our study needed a time effective measurement of general cognitive functioning in the 
clinical groups MDD and MDDA, that we assume do not affect intellectual functioning 
directly like other clinical groups. We also choose SI and PC as representative subtests to 
estimate general cognitive functioning/intelligence due to the adequate correlations with VIQ 
(.76) and PIQ (.56), and the time aspect, respectively.
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Table 1. Demographic and clinical characteristics
Table 1 displays descriptives of mean values (M) and standard deviations (SD) on 
demographic and clinical characteristics.
Note. MDD = Unipolar Major depressive disorder, MDDA = MDD with co-morbid anxiety Disorder, HC = 
Healthy controls, BDI-II = Beck Depression Inventory-II, BAI = Beck Anxiety Inventory, GAF = Global 
Assessment Scale (Symptom and Function; DSM-IV), General cognitive functioning estimated from WAIS-III
subtests; Picture Completion and Similarities.
3.5. Neuropsychological assessment
All participants underwent a battery of neuropsychological tests and paradigms administered 
by a trained test technician or a clinical psychologist trained in standardized assessment. Most 
tests are traditional neuropsychological tests that possess acceptable psychometric properties 
and have both extensive empirical and are theoretically based. Subjects were tested 
individually in well suited locations. Approximate total time required for clinical evaluation 
and neuropsychological testing varied from 3 hours up to 7 hours depending on different
factors. Neuropsychological tests were applied, which according to research, have been found 
to measure cognitive functions that often are impaired in MDD and MDDA. The tests load on 
the main cognitive domains: attention, memory and executive functions and the subfunctions 
involved. 
MDD
(n=37)
MDDA
(n=24)
HC
(n=92)
M SD M SD M SD
Age (years) 44.2 12.3 35.5 14.2 35.7 12.0
Age range (min - max) 18.0 60.0 18.5 60.0 19.0 61.0
Education (years) 15.8 3.2 13.5 2.3 16.4 2.5
BDI-II 21.3 11.1 25.4 7.4 2.1 2.7
BAI 11.7 8.3 18.7 6.7 2.1 2.5
Symptom-GAF 60.2 12.1 53.8 8.5 95.6 7.3
Function -GAF 63.6 13.8 55.2 10.1 96.7 5.6
General Cognitive Functioning 11.1 2.1 9.3 2.6 12.2 2.5
Age of Onset first MDD episode 33.5 14.4 30.1 16.1
n % n % n %
Gender
Male 14 37.8 11 45.8 29 31.5
Female 23 62.2 13 54.2 63 68.5
Handedness
Right 35 94.6 24 100 81 88
Left 1 2.7 0 0 11 12
Ambidextrous 1 2.7 0 0 0 0
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3.5.1. ANT
By including Stroop and ANT we intended to tap both higher-level cognitive effortful 
functions as well as more basic level attentional functions derived from Posner’s cognitive 
model. The Attention Network Task (ANT; Fan et al., 2002) was developed as a way to 
operationalize and measure the efficiency of each of the proposed networks; alerting, 
orienting and executive attention, within a single non-verbal task.
In the experimental ANT paradigm, one of four possible cues precedes a target arrow 
surrounded by congruent and incongruent arrows. Orthogonal subtraction scores provide a 
measure of each network (See Fig 1d). Participants are shown the successive presented 
stimuli on a computer screen and there are 4 cue conditions and 3 target conditions, as shown 
in Fig 1a and 1b. Stimuli consisted of a row of 5 visually presented horizontal black lines, 
with arrowheads pointing leftward or rightward. The target was a leftward or rightward 
arrowhead at the centre. Subjects respond on buttons on keyboard, depending on the direction 
of the target arrows in the centre. The target arrows are flanked by neutral, congruent or 
incongruent distracters (conflict). Before presentation of the target, subjects are either given a 
spatial cue (orienting), a centre temporal cue (alerting) or no cue (control condition). In the 
congruent condition, all 5 arrows point in the same direction. In the incongruent condition, the 
arrows that flank the target point in the opposite direction to the target arrow. Thus, there is 
response conflict in the incongruent condition, but not in the congruent condition. In the 
neutral condition, no flanker arrows appear. When the target display appears, the task is to 
indicate as fast and accurately as possible which way the target arrow is pointing. RT is 
recorded to the nearest millisecond. 
Efficiency of the alerting network is examined by changes in RT resulting from a warning 
signal. Efficiency of orienting is examined by changes in RT that accompany cues indicating 
where the target will occur. The efficiency of the executive network is examined by requiring 
the subject to respond by pressing two keys indicating the direction (left or right) of a central 
arrow surrounded by congruent, incongruent or neutral flankers. 
ANT consisted of a 24 trial practice block and three experimental blocks of trials. Each block 
consisted of 96 trials. The presentation of trials was in random order (See fig 1a-d)
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Fig 1 a-d.
(http://www.sacklerinstitute.org/users/jin.fan/; 2010).
3.5.2. D-KEFS Color-Word Interference Paradigm (Stroop)
A paradigm often used to study attention is the Delis-Kaplan Executive Function System (D-
KEFS) Color-Word Interference Test (Stroop) (Delis et al., 2001; Stroop 1935).
Stroop is designed to measure higher level attentional control/executive control of attention 
by involvement of conflict. The D-KEFS paradigm is proposed to measure executive control 
of attention by involvement of conflict. The task requires response to one aspect of a stimulus, 
while ignoring a more dominant aspect. The Stroop effect refers to the difference in color-
naming performance between congruent (e.g. the word green printed in green color) and 
incongruent (e.g. the word green printed in red color) stimuli. The D-KEFS Stroop test 
consists of four trials, the first two consisting of reading words and naming the colors of 
words, respectively. The latter two are the incongruent task (conflict/inhibition) where the 
word and color are different, and the participant is to name the color of the word, and the last 
trial uses the same principle as the former but with some words enclosed within boxes which 
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then requires the participant to read the word instead of the printed color 
(switching/inhibition). There are four primary outcome variables based on reaction time (RT). 
There are also three primary contrast scores that may be computed, namely: inhibition versus 
color naming, switching/inhibition versus combined color and word naming, and 
switching/inhibition versus inhibition. Two additional contrast scores are also included: 
switching/inhibition versus color, and switching/inhibition versus word. Age effects are 
associated with trial 3 and 4, therefore all 4 outcome variables are standardized age-corrected 
scaled scores based on response time. 
3.5.3. The Paced Auditory Serial Addition Test (PASAT)
The Paced Auditory Serial Addition Test (PASAT; Gronwall, 1977) was chosen to measure 
the executive control of WM. PASAT is a test measuring working memory or working 
attention. The processing requires processing speed, attention and working memory capacity 
in accordance with CE function (Baddeley, 1986). In the present version, translated into 
Norwegian language and audiotaped by Landrø (Landrø et al., 2004), the subjects listen to an 
audiotape were 60 digits is read successive in a 2 second rate/2 second stimulus-interval. 
Instructions to the subjects are to add each one-digit number presented every 2 second to the 
immediately presented digit preceding it and orally present the sum to the administrator. 
Dependent variables are Total correct answers, Total Errors and Total number of No answers.
3.5.4. Hopkins Verbal Learning Test (HVLT-R)
To operationalize short term (STM) and long term memory functions (LTM) we choose 
Hopkins Verbal Learning Test (HVLT-R; Benedict et al., 1998) ) in this study, due to the high 
reliability and validity of the task supported by many studies. 
HVLT (Brandt, 1991) is considered a conventional neuropsychological method that taps 
verbal memory, and is divided into immediate recall, delayed recall and recognition. The 
HVLT revised version in this study consists of immediate recall/learning, delayed recall and 
recognition. HVLT-R is considered a conventional neuropsychological method. The test is 
administered in paper-and-pencil format. The test begins with three learning trials; 12 words 
are read aloud by the examiner  at a rate of seconds, and the subject is asked to freely recall 
them immediately after reading, and not consider the proper succession in which hey were 
read. The 12 words are grouped in taxonomic categories with 4 words from each of three 
semantic categories. The words recalled for each trial were recorded and total recall score 
recorded for the 3 trials. The 3 free recall trials were 20-25 minutes later followed by a 
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delayed recall trial (Trial 4), were the participants were asked to recall as many of the words 
from trial 1-3. Immediately following trial 4, a forced-choice recognition test is administered 
(Trial 5). In trial 5, a list of 24 words is read aloud (including 12 target words and 12 
distracters) and the participant is then asked to answer yes/no if the words were one of the 12 
from the previously target list words. The dependent variables (in addition to recognition) 
were a) verbal learning (sum of trials 1-3), b) retention/delayed recall and c) recognition 
ability. The former two variables (Immediate Recall and Delayed recall) were transformed 
into standard scores (T-scores) that are corrected for potential age differences. 
3.5.5. CANTAB
The Cambridge Neuropsychological Test Automated Battery (CANTAB, Cambridge 
Cognition, 2006) is comprised of computerized neuropsychological tests that examine various 
areas of cognitive function. The CANTAB tests are simple, computerized, non-linguistic and 
culturally blind, and allow us to break down executive control functions into cognitive 
components in order to define more readily which functions are impaired or spared. Three 
subtests from the CANTAB battery were selected and administered in Paper III;
ID/ED, SWM and SST, which correspond to the three functional areas according to Miyake et 
al.’s (2000) non-unitary model of executive functions, namely shifting (ID/ED), updating 
(SWM) and inhibition (SST), respectively.
In addition; a motor screening test (MOT) was administered in the beginning of the test 
session and serves as a simple introduction to the touch screen for the subject. If a subject is 
unable to comply with the simple requirements of this test it is unlikely that they will be able 
to complete other tests successfully. This test therefore screens for visual, movement and 
comprehension difficulties. Administration time is around 3 minutes. This test has two 
outcome measures which measure the subject's speed of response and the accuracy of the 
subject's pointing
3.5.5.1. ID/ED
The Intra-Extra Dimensional set-shift task (ID/ED) is a test of rule acquisition and reversal.
The task assesses the ability to maintain attention to different examples within a stimulus 
dimension (ID stages), and the ability to shift attention to a previously irrelevant stimulus 
dimension (ED shifts) across nine stages. Subjects proceed to the next stage when a criterion 
of six consecutive correct responses has been reached.
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Stimuli consist of four rectangular boxes—to the top and bottom and to the right and left of 
centre, appear on the screen. Two of these contain the test stimuli, but the boxes used changes
from trial to trial. Two artificial dimensions are used in the test: colour-filled shapes (purple)
and white lines (see fig.2) Simple stimuli are made up of just one of these dimensions, 
whereas compound stimuli are made up of both, namely white lines overlying colour-filled 
shapes. 
The subject starts by seeing two simple colour-filled shapes, and must learn which one is 
correct by touching it (simple discrimination which varies just along one of the two 
dimensions). Feedback for responses are in the form of the words correct and wrong, 
presented respectively in green and red lettering above the middle two boxes and teaches the 
subject which stimulus is correct, and after six correct responses, the stimuli and/or rules are 
changed. Subjects progress through the test by satisfying a set criterion of learning at each 
stage (6 consecutive correct responses). If at any stage the subject fails to reach this criterion 
after 50 trials, the test terminates.) The test proceeds through a number of stages, each with a 
different contingency, up to a maximum of nine. For each, continuation to the next stage is 
dependent on a criterion of six successive correct discriminations being reached (Robbins et 
al., 1998; Downes et al., 1989).
Following the initial simple discrimination (SD), in the remaining subsequent
eight stages the contingencies are reversed (i.e. the previously correct response becomes 
incorrect and vice versa) and in the third stage the second dimension the compound stimulus 
(each dimension paired together) is introduced in two of the response boxes.
For this and all subsequent stages, exemplars of the different dimensions were paired in a 
pseudo-random fashion so that all four possible compound stimuli were used, with the 
constraint that runs of no more than three trials with the same pairings were allowed, but with 
reversals and new exemplars of both dimensions introduced; the intradimensional shift (IDS), 
but the relevant dimension (i.e. shapes or lines) was unchanged from stage 1. (Every new 
stimulus can be regarded as IDS). For the penultimate stage, the extradimensional shift 
(EDS), new exemplars were again introduced, but success at this point depended on the 
participant shifting response set to the exemplars of the previously irrelevant dimension. The 
two performance variables of interest are the number of stages completed, and the total error 
score adjusted for whether the entire task is completed (Kaplan et al., 2006).
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Figure 2:
3.5.5.2. SWM
Spatial Working Memory (SWM) is a test of the subject's ability to retain spatial information 
and to manipulate remembered items in working memory. It is a self-ordered task which 
requires subjects to search for hidden “tokens” within a spatial array of coloured boxes. By 
touching the boxes and using a process of elimination, the subject should find one blue 
‘token’ in each of a number of boxes, and then use them to fill up an empty column on the
right hand side of the screen (see fig.3). The number of boxes is gradually increased until it is 
necessary to search a total of eight boxes. The colour and position of the boxes used are 
changed from trial to trial in order to discourage the use of stereotyped search strategies. The 
participants were instructed that at any one time there would be a single token hidden inside 
one of the boxes. Their task was to search until they found it, at which point the next token 
would be hidden. The key instruction was that, once a blue token had been found within a 
particular box, that box would not be used again to hide a token for that particular trial. Since
every box was used once, the total number of blue tokens to be found on each trial 
corresponded to the number of boxes on the screen.
Outcome measures of interest are a “between” errors score, which is calculated when a 
subject returns to a square where a token was already found in a previous trial. This assesses 
the accuracy of working memory, as a strategy measure is derived; i.e. a subject’s ability to 
adopt a systematic search strategy: a lower strategy score reflects more efficient task 
performance on SWM (Owen et al., 1990; Weiland-Fiedler et al., 2004).
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Figure 3:
3.5.5.3. SST
The Stop Signal Task (SST) is a classic stop signal response inhibition test (Logan et al., 
1984; Logan et al., 1997; Osman et al., 1986). It uses staircase functions to generate an 
estimate of stop signal reaction time. The test gives a measure of an individual’s ability to 
inhibit a prepotent response. The term “response inhibition” refers to cognitive processes 
enabling executive control over prepotent responses in accordance with changing situational 
demands.
The test was administered on a laptop computer connected to two external speakers and a 
two-button press pad. SST consists of two parts. In the first part, the subject is introduced to 
the press pad, and told to press the left hand button when they see a left-pointing arrow and 
the right hand button when they see a right-pointing arrow. There is one block of 16 trials for 
the subject to practice this. This practice is used to build up a prepotent response.
In the second part, the subject is told to continue pressing the buttons on the press pad when 
they see the arrows, as before, but, if they hear an auditory signal (a beep) emitted randomly
form the computer, they are instructed not to respond/ withhold their response and not press 
the button (i.e. inhibit the prepotent response). They are further instructed that they will not 
always be able to stop, but sometimes they will, and encouraged to try their best (see fig.4)
The main outcome variable of interest for our purpose is the stop signal reaction time (SSRT), 
which is an estimate of the subject’s response time to the stop signal, i.e. the time it takes to 
react to the stop signal by inhibiting the prepotent response to the go signal (i.e. the time 
required to inhibit a response after it has been initiated). SSRT is estimated by subtracting 
Stop signal delay (SSD) from mean Go signal reaction time (RTonGT).
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Figure 4:
3.5.5.4. Psychomotor speed
In addition to the main variable of inhibition on the SST task, an outcome measure of reaction 
time on Go trials (GoRT), an indicator of psychomotor speed, was included.
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3.6. Statistical analyses
Data analysis was completed by means of SPSS version 16.0 (SPSS Inc., Chicago, IL, USA)
for Papers I-III.
3.6.1. Demographic variables
A series of one-way analyses of variance (ANOVAs) and Chi-square tests was conducted to 
compare the three groups across the demographic variables: age, education level, general 
cognitive functioning, gender, handedness and age of onset first depressive episode, followed 
by post hoc tests with Bonferroni corrections to determine which groups differed.
3.6.2. Paper I.
There were conducted two multivariate analysis of covariance (MANCOVA), followed by 
separate ANCOVAS and post hoc tests with Bonferroni corrections to compare the two 
clinical groups (MDD, MDDA) and HC with ANT and Stroop as dependent variables. The 
dependent variables were measured at an individual level, while simultaneously controlling 
for age, gender and education level and adjusted for multiple comparisons with Bonferroni 
corrections. Median RTs for each cue type and flanker type were calculated for each 
participant, and Alerting, Orienting and Executive attention were calculated. Analysis of 
variance (ANOVA) was performed to compare the MDD and MDDA groups on the effect of
number of earlier depressive episodes. In addition, Pearson correlations between scores on 
BDI and BAI and the dependent variables for the clinical groups were performed.
3.6.3. Paper II
There were conducted two multivariate analysis of covariance (MANCOVA), followed by 
separate ANCOVAS and post hoc tests with Bonferroni corrections to compare the two 
clinical groups (MDD, MDDA) and the HC group with HVLT and PASAT as the dependent 
variables. The dependent variables were measured at an individual level, while 
simultaneously controlling for age, gender and education level and adjusted for multiple 
comparisons with Bonferroni corrections. We also performed pairwise comparisons between 
the two clinical groups without adjusting for the family-wise error rate. Analysis of variance 
(ANOVA) was performed in the following to compare the MDD and MDDA subjects with
respect the effect of number of earlier depressive episodes, in addition to a Pearson’s
correlations between scores on BDI and BAI and the dependent variables, and between 
PASAT and HVLT-R T-scores for the clinical groups.
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3.6.4. Paper III
Multivariate analysis of covariance (MANCOVA) was first used to compare the two clinical 
groups (MDD and MDDA) and the healthy controls (HC) on the combined score of the six 
dependent variables measured at the individual level: ID/ED stages completed, ID/ED Total 
errors adjusted, SWM strategy, SWM between errors, SST RT on Go trials, and SST SSRT,
while simultaneously controlling for age, gender and education level adjusted for multiple 
comparisons with Bonferroni corrections. Follow-up univariate analysis of covariance 
(ANCOVA) was then performed to detect which of the six dependent variables the three
groups differed significantly from each other in mean scores. Finally, ANCOVAs was also 
used to compare the MDD group and the MDDA group on the six dependent variables 
controlling for the number of earlier depressive episodes and age of onset of first depressive 
episode. In addition, Pearson correlations between scores on BDI and BAI and the dependent 
variables for the clinical groups were performed.
3.7. Ethical considerations
The study was approved by the Regional Committee for Medical Research Ethics, Norwegian 
Social Science Data Services (NSD) and adhered to the Helsinki Convention. Written 
informed consent was obtained from all participants after provision of a complete written and 
oral description of the study. They were informed that at any time, without any explanation 
they could withdraw from the study. There were no participants that withdrew during the 
study.
None of the participants were in a patient relationship with the researcher and test 
administrators. As a service for participation the participants and their therapists were given 
the opportunity to receive an individual report of their results, both written and oral. This was
done directly to the participant, but also often together with their therapist, depending on the 
participants wishes.
A dilemma that concerns the use of diagnostic interviews and self report questionnaires 
regarding the healthy comparison subjects may be that they uncover symptoms and 
experiences they were not prepared to uncover or discuss. However, they were all informed 
about the instruments beforehand, about the anonymity and the right to withdraw at any 
moment without any explanation. In addition, the test administrators were prepared to handle 
theses situations as professional clinical psychologists, and when needed guide and help the 
participants for further treatment.
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4.0. RESULTS
4.1. Demographic results for Papers I-III
Differences between the groups were found regarding age [F(2, 152)=6.637; p<.01], 
education level (ISCED) [F(2, 152)= 9.67 ; p< .001] and general cognitive functioning 
(WAIS-MEAN) [F(2, 152)= 14.055; p< .001]. There were no significant between-group 
differences in terms of gender distribution [2 (2) = 1.85, p= 0.397] and handedness [2 (4) = 
8.60, p= 0.072].
The patients with MDD differed significantly from the HC group regarding age, the mean age 
being older for MDD. The MDDA group differed significantly from the MDD group, the 
mean age being younger for the former. There were no statistical differences in age between 
MDDA and HC. According to general cognitive functioning, the MDDA group had 
significantly lower mean than HC and MDD. The MDDA differed significantly from the HC 
group regarding education level, the former having lower mean educational level. Since 
educational level and estimated general cognitive functioning was correlated we did not enter 
the latter in the MANCOVA. Although there was a significant difference between the co-
morbid group and healthy controls on the general cognitive measure, the patients nevertheless 
performed well within the normal range. As compared to the formal norms the performance 
level equals less than one-third of a standard deviation from the mean.
As for the facets: number of depressive episodes, age of onset first depressive episode and 
depressive and anxiety symptom severity; there were no significant group differences 
between the two clinical groups MDD and MDDA regarding age of onset first depressive 
episode. (There are nine missing values in the MDD group and four missing values in the 
MDDA group, due to difficulties in gaining accurate information about age of onset from 
these subjects), neither did the groups differ significantly regarding number of depressive
episodes. The MDD and MDDA groups did not differ significantly on depressive symptoms 
measured with BDI-II, but MDDA had a higher score on BAI than MDD [F(2, 151) = 
115.259, p< 0.001].
Furthermore, we performed ANCOVA`s to test whether there was a difference between 
MDD and MDDA on the dependent variables (ANT, Stroop, PASAT, HVLT, CANTAB-
variables) respectively, when controlling for number of earlier depressive episodes and age of 
onset first depressive episode. Our results show that neither number of episodes nor age of 
onset of first depressive episode significantly related to performance on either of the 
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dependent performances. The exception was on the variable Word in Stroop, but since this 
variable did not show significant differences between the diagnostic groups, this may indicate 
that the number of episodes may be independent of diagnosis. Hence, including number of 
depressive episodes and age of onset as covariates in the analyses, did not alter the results, 
i.e., there were no significant differences in mean scores on the dependent variables between 
the two groups.
Regarding symptom severity, we performed correlations between scores on BDI-II and BAI
and the dependent variables for both the MDD and MDDA groups. The correlations between 
scores on BDI-II and BAI and the dependent variables showed no significant correlations 
between BDI-II on any of the variables on ANT and Stroop, but BAI correlated with Alerting 
(r= -.281, p< .05) and Orienting (r= -.277, p< .05) on ANT, and with Inhibition (r= -.268, p<
.05) on Stroop. Both BDI-II and BAI correlated significantly with the variables Total correct
(BDI: r= -.286. p< .05; BAI: r= -.360, p< .01) and No answer (BDI: r= .259, p< .05; BAI: r=
.354, p< .01)) on PASAT. BDI correlated significantly with Immediate Recall (r=-.284, p=
.05), and both BDI and BAI correlated significantly with Delayed recall (BDI: r= -.384, P<
.01; BAI: r=-.339, p< .01) on HVLT. There were no other significant correlations between 
BDI-II and BAI on any of the other variables for the two groups.
4.2. Neuropsychological results Paper I
The MANCOVA showed a significant overall group difference in performance on the Stroop 
task regarding the four primary outcome variables, F(8, 290)= 3.44, p= .001. Follow-up
ANCOVAs and post hoc tests demonstrated significant differences for the variables Color, 
Inhibition, and Switching. The MDDA group had significantly longer RT than HC on Color, 
Inhibition, and Switching, and significantly longer RT on Switching than the MDD group. 
There were no other statistically significant differences between any of the groups on the 
variables. When using the three primary and two additional contrast scores, the MANCOVA 
showed a significant overall group difference in performance, F(12, 286)= 2.916, p= .001.
Follow-up ANCOVAs and post hoc tests demonstrated significant differences between 
MDDA and HC on the primary contrast scores: Switching versus a combined Color-Word 
score, Switching versus Inhibition, and the additional contrast scores: Switching versus Color 
and Switching versus Word. There were no other statistically significant differences between 
any of the groups.
Regarding performance on the ANT, the MANCOVA showed a significant overall group 
difference, F(8, 276)= 3.300, p< .002. Follow-up ANCOVAs and post hoc tests demonstrated 
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significant differences regarding the variable Alerting: MDD showed significantly higher RT 
compared with HC. There were no statistically significant differences between any of the 
groups on the variables Orienting, Executive, and Overall Accuracy. The standard deviation 
on all of the four ANT measures was substantially larger in the two clinical groups when 
compared with HC. This meant that the assumption of homogeneity of variance did not hold. 
Logarithmic transformation of all five dependent variables and the exclusion of two outliers 
in the clinical groups produced acceptable values for the test of homogeneity of variance on 
all dependent variables. Repeating the above mentioned analyses using the transformed 
dependent variables gave the same conclusion in terms of the statistical significance of the 
group differences and the post hoc test, that is, a significant group difference on Alerting (F =
8.66, p< .001), and the MDD showing significantly higher RT compared with HC. In
addition, a Kruskal–Wallis nonparametric test for differences between the groups was also 
performed. This gave the same conclusion.
4.3. Neuropsychological results Paper II
MANCOVA demonstrated significant overall group differences in performance on PASAT 
[F(6, 288)=4.452, p< .001]. Follow-up ANCOVAs and post-hoc tests demonstrated 
significant differences regarding the variables Total correct and No answer, where the clinical 
groups MDD and MDDA performed with fewer Total correct answers and more cases of No 
answers compared to the HC group. There were no other statistically significant differences 
between any of the groups on the variable errors. The standard deviation on all three 
dependent variables on PASAT was substantially larger in the two clinical groups compared 
to the HC group. This meant that the assumption of homogeneity of variance did not hold. 
Logarithmic transformation of all three dependent variables produced non-significant values 
for the test of homogeneity of variance on all dependent variables. Repeating the above-
mentioned analyses using the transformed dependent variables resulted in the same 
conclusion in terms of the statistical significance of the group differences. No outliers were 
found within any of the three groups.
Since we had a priori hypothesis concerning the differences between the two clinical groups, 
Bonferroni corrections may be too conservative. Therefore, we also performed pairwise 
comparisons between the two clinical groups without adjusting for the family-wise error rate. 
The results of these comparisons revealed that the MDDA group had a significantly lower 
score on Total correct answers (p= .040, two-tailed) and a nearly significant lower score on 
errors (p= .053, two-tailed) compared to the MDD group. 
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The MANCOVA did not demonstrate a significant overall group difference in performance 
on HVLT [F(6, 292)= 1.574, p= .171]. However, due to the expected direction of the results, 
we performed follow-up ANCOVAs and post-hoc tests. The results demonstrated that there 
were near-significant overall group differences for variables Delayed Recall (p= .051) and 
Recognition (p= .058). Post-hoc tests demonstrated that the MDDA group showed trends 
toward lower scores compared to the HC group on variables Delayed Recall (p= .050) and
Recognition (p= .052). There were no statistically significant differences between any of the 
groups for the variable Immediate Recall. As previously mentioned, Bonferroni corrections 
may be too conservative in situations where a priori hypotheses concerning group differences 
are present. Therefore, we also performed pairwise comparisons without adjusting for the 
family-wise error rate. The results revealed no significant differences between the two MDD
and MDDA clinical groups on any of the HVLT variables, but they confirmed significant 
differences between the MDDA and HC group for Delayed Recall (p= .017, two-tailed) and 
Recognition (p= .017, two-tailed).
4.4. Neuropsychological results Paper III 
The MANCOVA demonstrated a significant overall group difference in performance on the 
CANTAB tests [F(12, 284) = 2370, p< 0.01] Follow-up ANCOVAs and post hoc tests 
demonstrated significant differences between the MDDA group and HC on two of the 
dependent variables: ID/ED total errors adjusted and SWM between errors. The MDDA 
group performed the tasks with more errors than the HC. There were significant differences 
between the MDD group and the HC group on SST RT on Go Trials. MDD performed the 
task with slower psychomotor speed compared to the HC group. There were no statistical 
significant differences between the clinical groups on any of the other variables.
A significant Pearson correlation was found for the MDDA group between BAI and ID/ED; 
total errors adjusted (r= 0.48, p< 0.05). There were other no significant correlations for the 
SWM; between errors, and no significant correlations were found between BDI and the two 
CANTAB measures regarding the MDDA group.
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5.0 SUMMARY OF PAPERS
5.1. Paper I
Background: The aim of this study was to explore if the divergent results regarding
attentional functions in patients with mood disorders are due to selective impairments in 
higher level or more basic and distinctive attentional subcomponents. Method: We compared 
out-patients with current MDD (n=37) and MDD with co-morbid anxiety (MDDA) (n=24), to 
healthy controls (n=92) on Stroop and Attentional Network Test. Results: The current data 
indicate that significant impairment in attentional functions correspond with the presence of 
MDD and MDDA. MDDA displayed significantly impaired performance on Stroop variables, 
and MDD were significantly impaired in the Alerting function in ANT. Number of episodes, 
age of onset first depressive episode was not significantly related to performance on neither 
Stroop nor ANT variables. Symptom severity measured with BDI-II did not correlate 
significantly with any of the dependent variables, but BAI correlated significantly with 
Alerting and Orienting on ANT, and with Inhibition on Stroop.
Conclusion: These results show impairments on different levels of attention in mood 
disorders. MDDA show impairments on higher level executive attention functions and MDD 
display deficit at a more basic attentional level. The findings suggest that including co-morbid 
anxiety in MDD is imperative for future research. 
5.2. Paper II
Background: The aim of this study was to examine both executive control of verbal working 
memory and verbal learning as well as long-term storage function. Method: We compared 
outpatients with current MDD (n=37) and MDD with co-morbid anxiety (MDDA; n=24) to 
healthy controls (n=92) on PASAT and HVLT. Results: Both patient groups showed
impaired working memory test performance compared to healthy controls. Patients with 
MDDA performed significantly below the MDD group. Only patients with MDDA displayed 
deficient long-term memory function compared to healthy controls. Number of episodes and
age of onset first depressive episode were not significantly related to performance on neither
PASAT nor HVLT variables. Both BDI-II and BAI correlated significantly with the variables 
Total correct and No answer on  PASAT. BDI correlated significantly with Immediate Recall, 
and both BDI and BAI correlated significantly with Delayed recall on HVLT.
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Conclusion: The present results show impairments in various memory functions in patients 
presenting depression and depression with co-morbid anxiety disorder. 
5.3. Paper III
Background:  Impaired cognitive control functions have been demonstrated in both major
depression (MDD) and anxiety disorder (A), but few studies have systematically examined 
the impact of MDD with co-morbid A (MDDA), which is the main aim of this study. 
Method: We compared patients with MDD (n=37) and MDD with co-morbid anxiety
(MDDA; n = 24) to a group of healthy controls (HC; n = 92) on three subtests from the 
Cambridge Neuropsychological Test Automated Battery; intra–extra dimensional set –shift 
task, stop signal task, and spatial working memory. These tasks correspond to a theoretical 
model consisting of three separable but interrelated executive control functions: Shifting, 
Inhibition, and Updating. A simple psychomotor speed measure was also included. Results: 
After controlling for age, gender, and education level, the results showed that the MDDA 
group displayed significantly impaired performance on the functions Shifting and Updating 
compared to HC. There emerged no significant differences between any of the patient groups 
and HC regarding Inhibition. The pure MDD group did not display dysfunctions relative to 
the HC group on the main executive control variables, but displayed slowed psychomotor 
speed. Contrary to expectation there were no significant differences between the MDDA and 
the MDD groups. Number of episodes, age of onset first depressive episode were not 
significantly related to performance on any of the dependent variables.
Symptom severity measured with BDI-II and BAI did not correlate significantly with any of 
the variables for the clinical groups combined. Conclusion: Co-morbid anxiety should be 
taken into account when studying cognitive control functions in major depression.
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6.0. DISCUSSION
The present work is based on a study of neuropsychological functioning in patients with 
unipolar major depression with and without co-morbid anxiety disorders compared to healthy 
controls. The neuropsychological test battery consisted of tests chosen to explore selective 
functions that have shown divergent results in the research field regarding MDD, and that 
have been little investigated as regards to MDDA. The focus has been basic and distinctive 
attentional subcomponents to different levels of memory functions and to subcomponents of 
higher level executive functions. Although the presents study presents some potentional 
limitations, it contributes knowledge to the existing contradictory and sparse literature of 
understanding neuropsychological performance in patients with MDD and co-morbid anxiety 
disorders. In addition we also wanted to determine whether cognitive deficits vary as a 
function of characteristics such as number of depressive episodes, symptom severity and age 
of onset first depressive episode.
6.1. Discussion of the main findings
The aim of paper I was to investigate if the divergent results in studies of attention in MDD 
and MDDA are due to impairments in distinctive attentional subcomponents and/or that the 
patient groups display impairments on different levels of attention. Our results showed that 
MDD and MDDA exhibit impairments at different levels of attention and on specific 
subcomponents. MDD displayed impairment on the basic level subfunction: alerting, whereas 
MDDA showed specific impairments in the higher level attentional functions of Switching 
and switching/inhibition compared to HC. Differences between MDD and MDDA were only 
found regarding switching/inhibition. These results show the specific effects of co-morbid 
anxiety on attentional functioning in MDD. Furthermore, the results support the “cognitive 
effort”-hypothesis and contradicts the “cognitive speed”-hypothesis in that it is specifically 
the higher level switching/Inhibition component that is  affected in MDDA compared to 
MDD,  not any of the other more basic variables.
In paper II, the aim was to examine different verbal memory functions, from the central 
executive aspects of WM to learning and LTM. The results showed that both patient groups 
show impairments in different memory functions in that they displayed WM deficits 
compared to HC, with MDDA performing significantly worse than MDD.  Only the MDDA 
group displayed deficits in LTM compared to HC. These results reflect the effect that co-
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morbid anxiety has on different verbal memory functions in MDD. It seems that it is the 
anxiety component in the MDDA group that contribute to deficits in LTM and to the worse 
performance than MDD regarding WM. These results are also in line with the cognitive 
effort-hypothesis, in that MDDA showed a specific deficit in a more higher-order function 
and worse deficit than MDD in WM. As regards to working memory, WM dysfunctions in 
MDD patients have been reported in other studies (Landrø et al., 2001; Pealecke-Habermann 
et al., 2005; Porter et al., 2003) and a recent review has highlighted deficits in WM as central 
in MDD (DeBattista, 2005). Our results show that when the anxiety component is added, the 
effect on WM capacity is worse than in MDD alone.
In Paper III we investigated three separable higher-order executive control functions 
according to Miyake et al.’s (2000) theoretical and empirical based model. We found that 
only MDDA showed impaired performance on two of the subfunctions; Shifting and 
Updating, whereas MDD only displayed slowed psychomotor speed compared to HC. This 
adds information to the existing contradictory literature, regarding MDD where both presence 
of inhibition deficits (Lampe et al., 2004; Paelecke-Habermann et al., 2005) and no deficits 
have been found (Degl’Innocenti et al., 1998). The mixed findings may, according to our 
results, be due to unaccounted for co-morbid anxiety in MDD.
To sum up papers I-III: MDD showed basic attention deficits, working memory deficits and 
slowed psychomotor speed compared to healthy controls. MDDA showed deficits in working 
memory, long term memory, higher order attentional control functions (switching/inhibition) 
and the executive subfunctions inhibition and updating compared to healthy controls. MDDA 
compared to MDD, showed deficits in switching/inhibition, and worse performance in 
working memory than MDD. 
The present study support the notion that the co-morbidity of MDD and A may contribute to 
enhanced neuropsychological impairment. Where some studies find that the pure MDD and 
anxiety disorders do not exhibit significant impairments, it seems that it may be the presence 
of co-occurrence of these two disorders that increases the likelihood of cognitive dysfunctions 
in patients with MDDA.
The results also confirm earlier findings that patients with current MDD show impairments 
regarding basic level attention (Alerting), working memory and psychomotor retardation 
compared to healthy controls. This is in line with Reppermund et al. (2009), that found no 
selective or specific deficits, but merely a generalized, unspecific impairment profile in 
depression, whereas a high number of the patients were impaired in basic attentional tasks 
(e.g. 56% in alertness). They propose that due to the interrelations between cognitive 
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processes, these attentional deficits might be responsible for impairments in other cognitive 
domains. They propose the notion that if a sufficient attentional level cannot be reached or 
maintained, a global unspecific reduction of performance in all cognitive domains may result 
and are in line with the final common pathway disorder hypothesis proposed by Mialet et al. 
(1996) and Zihl et al. (1998).
Regarding MDDA, these results adds knowledge to the existing literature, by contradicting
the findings of no group differences by Castaneda et al. (2010) and Herrera-Gusmàn et al. 
(2009), but supporting both Basso et al`s. (2007) and Airaksinen et al`s. (2004) findings that 
both MDD and MDDA showed worse memory functions than HC, but MDDA significant 
worse than the other groups. Basso et al. (2007) found that executive function was specific to 
the MDDA group, in accordance with our results. However, we did only find the MDD group 
to show psychomotor slowing and not MDDA as in Basso et al`s study. That MDDA 
performed worse than MDD on higher order functions and did not show psychomotor slowing 
as MDD did, may be due to the impact that the co-morbid anxiety disorder in MDD has on
the central executive attention in WM, and minor impact from differences in information-
speed processing. Another argument is that anxiety patients often exhibit a fear of new or 
unfamiliar situations, and that the test-situation itself is sufficiently threatening to arouse a 
significantly greater amount of manifest anxiety in the MDDA group than in the MDD group. 
Hence, the anxiety component may then contribute to increased information processing 
speed/acceleration and the depression component to decreased speed, so that in the MDDA 
group these inverse tendencies may have been counterbalanced.
WM may be sensitive to information-processing speed, but the comparisons between MDDA 
and MDD still show that MDDA have significant lower scores than MDD, hence that we 
consider this to be due mainly to dysfunction in the CE aspect of WM in MDDA and less 
impaired information-processing speed. Miyake et al`s. (2000) approach focusing on the sub 
functions of executive control functions, are related to the goal-directed attentional system 
and to the central executive earlier proposed by i.e. Baddeley et al. (1986) and Norman and 
Shallice, (1986; SAS). Eysenck et al. (2007) suggest that both inhibition and shifting involves 
using attentional control, except updating which they consider not to be directly concerned 
with attentional control. However, the three separable but highly inter-related functions 
proposed by Miyake et al. (2000) are also partially interdependent in their functioning, 
suggesting they all rely to some extent on the resources of the central executive or top-down 
attentional system (Eysenck et al., 2007). Relating this to our results, there seem to be only 
the impairments in the MDDA group that are directly related to higher level executive 
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control. Still, the differences in results across studies regarding which EF components that are 
spared or affected in MDD and MDDA may be due to methodological problems related to
differences in e.g. operationalizations of EF subcomponents. 
Effortful processing or cognitive load may broadly be related to the executive control of WM, 
or at a more basic level, the load on working memory in a task. So, the effort-hypothesis may 
explain our results regarding MDD as well as the MDDA. Lower level basic automatic 
functions, as opposed to higher-level effortful functions that require more cognitive load and 
effort, may be viewed as processing stages where the higher level functions are dependent on
the lower level subfunctions. 
Up to date, a consistent and clear-cut profile of cognitive impairments has not been 
established, and Mialet et al. (1996) have in a meta-analysis therefore interpreted the rather 
unspecific and contradictory cognitive deficit pattern in depression as a “final common 
pathway”-disorder, and highlight the role of attention and its executive components. The 
assumption is that there are supramodal functional networks that are affected and which 
represents the highest and final level of integration of regional cognitive networks subserving 
e.g. information processing, attention and memory. Support for this theory comes from 
imaging studies (Kane & Engle, 2002) and from studies on depressed subjects where it has 
been shown that PFC plays the dominant role as a final common pathway (Austin et al., 2001;
Rogers et al., 2004). Cognitive processing is seen in a diagram as a hierarchy, where EF 
exhibits the highest level and includes tertiary integrations areas in the brain. Memory (WM, 
learning, recall) exhibits medium level and secondary integrations areas in the brain, whereas 
both dependent on primary functions such as alertness, attention and activation. Working 
memory is often regarded as a factor in EF. WM is an active system that manipulates 
information necessary for other more complex and higher order functions, and good WM 
function often correlates with good function in other cognitive domains.
Knudsen (2007) also provides a conceptual framework that proposes four fundamental 
processes to attention that each makes a distinct and essential contribution. Three voluntary 
control attentional processes: working memory, top-down sensitivity control and competitive 
selection operating in a recurrent loop, in addition to an automatic bottom-up filtering for 
salient stimuli. WM and attention are according to this model inextricably inter-related. WM 
represents the objects of attention and comprises of competitive processes where multiple 
types of information compete for full control of the circuitry underlying WM, that are widely 
distributed in the brain with the PFC acting as an executive controller. According to Knudsen
(2007), a benefit of this framework is in interpreting the symptoms of which many disorders 
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may affect attention in different ways. Relating this to the results in our study, it seems that 
what differentiate MDDA and MDD is the way MDDA affects WM and top-down 
competitive selection, whereas MDD affects more bottom-up processes.
In our study we included patients with different co-morbid anxiety subtypes, and this may 
contribute to the discussion if the interaction of different anxiety subtypes and MDD may give 
influence on the mixed results in the field. However, we thought it reasonable to aggregate 
patients with different anxiety disorders in the MDDA group for the purpose of this research.
Despite the heterogeneity and the different diagnostic subclassifications among anxiety 
disorders, much is shared between them. Anxiety disorders, according to LeDoux (1996) all 
share an experience of anxious distress, avoidance of situations that provoke such distress and 
anxiety symptomatology is commonly shared between these disorders (Kruger & Finger, 
2001; Basso et al., 2007). High rates of shared symptom variance exist among these even with 
administration of structured diagnostic interviews and psychometrical pure self-report 
measures (Mineka et al, 1996; Basso et al 2007). Neural substrates of the fear response are 
also presumed to be uniform across anxiety disorders (LeDoux, 1996). Up to date, there are 
only a few studies that address the neuropsychological functioning in a variety of anxiety 
subtypes, and evidence from this research presents a mixed pattern of results (Airaksinen et 
al., 2005). The inconsistent and mixed results regarding anxiety subtypes may be due to the 
heterogeneity of the syndromes itself, and/or the high rate of co-morbidity that makes it 
difficult to obtain a “pure” sample.
Neither number of depressive episodes nor age of onset did affect the significant variables in 
our study, and this contradicts studies which show that both number of episodes and early age 
of onset for first depressive episode have shown to affect cognition in mood disorders (Basso 
& Bornstein, 1999b; Fossati et al., 2004; Paelecke-Habermann et al., 2005; Grant et al., 2001;
Kessing, 1998; Castaneda et al., 2008; Castaneda et al., 2010). However, the literature is 
comprised of rather mixed results, and our findings are in line with Grant et al. (2000) 
Reisches & Neu (2000) and Lampe et al. (2004). There are number of reasons why the 
database regarding cognitive functions and number of episodes is inconsistent, and additional 
risk factors may have had an impact in our study and also regarding the inconsistencies in the 
research field; length of first episode, loss events, genetic vulnerability, family history and 
previous hospitalization, information that we did not control for. Previous studies have 
typically not controlled age of onset and risk for recurrent depressive episode simultaneously,
and since they are moderately correlated and therefore not synonymous, this may be the 
reason for the mixed and often conflicting results.
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Depression and anxiety symptom severity, measured with BDI-II and BAI, both correlated 
with variables related to WM functions and long term memory functions. BDI correlated with 
Immediate recall and BAI with Alerting and Orienting and with Inhibition. Thus, even though 
our main focus was syndrome/diagnosis, it seems that symptom severity of depressive and 
anxiety may account for some of the variance. As mentioned earlier, the discussion whether 
cognitive dysfunction represent symptom or syndrome factors or an interaction is still under 
discussion. 
6.2. Possible implications of the findings for models of depression and anxiety
There are several discussions about the relationship between depression and anxiety in 
regards to differences and/or similarities; whether MDDA may represent a quantitatively
and/or qualitatively distinct clinical group from pure depression and anxiety. Or as the notion
says: “a whole is different from the sum in parts”.
Regarding the relation between depression and anxiety, Hirschfeld (2001) states that both 
disorders are manifestations of a single disorder. Is one disorder an epiphenomenon of the 
other? Numerous studies have documented the negative consequences of co-morbidity of 
MDD and anxiety on aspects at the symptomatic level and psychopathology; higher severity 
of illness, course, chronicity, recovery and relapse rates, suicide rates, psychosocial 
impairment and greater impairment of work functioning and higher hospitalization rate, while 
other studies report no effects of the co-occurrence of the two disorders. Tarsia et al. (2003) 
even suggest that mixed anxiety-depression may represent a distinct entity in which cognitive 
functions differ from that in both MDD and anxiety disorders.
The controversy between unitary versus dual models have been replaced by a more nuanced 
view where both disorders are posited to have both shared, common components and specific, 
unique components. Mineka et al. (1998) proposed an integrative hierarchical model in 
response to evidence of the substantial co-morbidity between mood and anxiety disorders. In 
the model each syndrome contains both a common and unique component. The shared 
component represents broad individual differences in general distress and negative 
emotionality. In addition, each disorder also includes a unique component that differentiates it 
from all the others. For instance, low positive emotionality is positioned to be specific to 
depression whereas autonomic arousal is characteristic to panic disorder (Gamez et al., 2007).
Other comparable findings of similarities of both types of disorders in addition to several 
common symptoms have been proposed. Depression and anxiety share a genetic vulnerability 
linked to the serotonin- and norepinephrine-system, a shared association between a 
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polymorphism in the serotonin transporter gene (5-HTT-LPR) and the personality trait of 
neuroticism has also been reported (Munafo et al., 2006). This also gives susceptibility to the 
same pharmacological treatment suggesting a similar underlying dysfunction (den Boer et al., 
2001). In addition to these similar risk factors and gender distribution (Pèlissolo & Lèpine, 
2001), other neuronal substrates have also been proposed as common for affective disorders.
Anderson (2010) suggests four key brain regions involved in affective disorders: a) Orbital 
prefrontal cortex (OPFC) and the Ventromedial prefrontal cortex (VMPFC), b) Dorsolateral 
prefrontal cortex (DLPFC), c) Hippocampus and Amygdala and d) Anterior Cingulate Cortex 
(ACC). Phenotypically the affective disorders are considered to have both common and 
distinct features. Common are their shared mood/emotion component and shared negative 
affect. Distinctions have be made regarding symptomatic heterogeneity, and that MDD show 
mood congruent memory biases, whereas anxiety display attention biases for threatening 
information. MDD have been linked to feelings of loss and hopelessness, while anxiety to 
threat and helplessness, consistent with findings of anticipated threat /danger in anxiety and
major loss event in the past for depressive (Beck & Emery, 1985; Brown & Harris, 1993; 
Mineka et al., 1998). Also, abnormalities in the regulatory mechanisms of the gamma-
aminobutyric acid (GABA) have been implicated due to response to treatment with 
benzodiazepines in anxiety (Kirkwood & Hayes, 2005). As mentioned, Osuch et al. (2000) 
used PET and found difference in patterns of cerebral metabolism between depression and 
anxiety symptom severity; this may imply that co-morbid depression and anxiety may exert 
neurobehavioral effects that differ from those observed in depression and anxiety alone.
In line with Mineka et al`s. (1998) quantitative approach and demonstrating that the size of 
general distress/negative affectivity component differs markedly across symptoms and 
disorders, Watson & Clark (2006) address the atheoretical DSM system and suggests a 
reorganization of the diagnostic classes and implementation of fully dimensional scheme that 
move away from the purely descriptive schemes to a system that reflects the more underlying 
causes of psychopathology e.g. genetics. As an example they suggest that generalized anxiety 
disorder (GAD) would be placed within the same diagnostic class as MDD, based on 
evidence of similarity; fenotypically (e.g. Krueger, 2001) and genotypically (Kendler et al., 
2003). In line with this, a study by Gamez, Watson, & Doebbeling (2007) suggests that both 
GAD and PTSD have more in common with MDD than with their anxiety counterparts. The 
model (see fig. 5) illustrates how the mood and anxiety disorders might be reorganized. They
further argue that the new scheme will model co-morbidity directly: strongly correlated 
syndromes are placed together, making it easier for clinicians and researchers to incorporate 
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co-morbidity. Also, the problem of within-disorders heterogeneity can be bypassed by 
adopting a fully dimensional taxonomy, according to Watson & Clark (2006).
Figure  5:
According to this model an alternative empirically based taxonomy of the mood and anxiety 
disorders will be replaced by distress and fear disorders under the umbrella term Internalizing 
disorders, which better captures co-morbidity as opposed to separation of mood and anxiety 
disorders. Moreover, they argue that both mood and anxiety disorders are strongly related, 
and should not be artificially separated into different diagnostic classes like in DSM 
diagnoses that they consider to be a pseudo-hierarchical, rational folk system that do not 
reflect highly co-morbid disorders.
In a more recent article, Watson (2009) reviews past and more contemporary models of the 
relation between depression and anxiety, and ends up with synthesizing the evidence into a 
quadripartite model that is supposed to represent the best aspects of these. In short, the model 
demonstrates that two quantitative elements need to be considered when analyzing the 
properties of symptoms – the level of specificity and the magnitude of the general distress 
variance. These elements can then be used to organise relevant symptoms into four groups 
that reflect varying combinations of distress and specificity (Watson, 2009). The use of 
theory-driven analyses and the quadripartite model may be a tool to properly address and 
understand the marked heterogeneity both between and within disorders like depression and 
anxiety that may be the cause of different cognitive impairments and lack of consensus across 
studies.
Can the constellation of findings shed light on these issues?
Our findings indicate that there may be the combination of syndrome MDD and A that result 
in many of the cognitive impairments seen in the literature regarding MDD. Some of the
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results are in accordance with a continuum model, where the MDD group can be placed 
between the HC and the MDDA groups with respect to neuropsychological functioning. On 
the other hand, there are also some indications of more basic, qualitative differences between 
MDD and MDDA along the bottom-up versus top-down dimension. However, the relation 
between aspects of neuropsychological functioning and overarching models of 
psychopathology is complex and should be more focused on in future research.
6.3. General methodological considerations
The inconsistent findings across studies in the research field may to a degree be explained by 
differences in study populations and measurement. The main findings in this thesis are not an 
exception. A number of potential methodological issues are related to sample characteristica, 
assessment measures and possible confounding variables that that may threaten the 
interpretations and generalizability of the current findings.
6.3.1. External validity
We aimed for a clinical sample representative for subjects in an outpatient setting both
regarding MDD and MDDA. Given the high prevalence rate in the population, the majority 
that seek professional help end up in a setting as policlinical outpatients, not inpatients.
Outpatients are also considered less severely ill than inpatients and thus more representative 
for a larger part of the population. Inpatients are also more likely than outpatients to display 
impaired cognitive function (Basso et al., 2007). Still, clinical samples versus population-
based samples may represent more selected and hence more severe. The sample of healthy 
controls, without any history of psychiatry and consisting of subjects interested in 
participating in a study focusing on cognitive functioning, is probably not representative for 
the general population in that they may represent an above average level of functioning and 
education level. The general high level of education in all the samples may be a problem 
concerning generalizabililty to other populations, especially internationally. Norwegians are, 
due to international standards, highly educated in general. 
The male-female ratio regarding MDD was as expected, as there are twice as much women 
seeking treatment for depression symptoms, whereas the ratio in MDDA was almost equal.
The healthy control group had a similar proportion of female-male-ratio as the MDD group.
Regarding representative considerations and selection biases, the patients participating in this 
study are patients that are in therapy and/or medicated. Patients that most often seek treatment 
and also see the advantage in participating in this kind of research project are often patients 
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with complaints and cognitive problems that affect their daily lives and occupation. The 
participants where given the opportunity for feedback regarding the test results by the test 
administrator, either alone or together with their therapist.
The patients were recruited through outpatient clinics in Oslo and close areas, mostly trough 
written information from their therapist, or from posters hanging in the waiting area in the
clinics they were attending. Hence, there was a majority of recruitment through information 
from the therapist, but they contacted us in a mix between getting an appointment through the 
therapist or through direct phonecalls to the administrators. So, it is difficult to know exactly 
the distribution of the “pure” self-referrals. Regarding the healthy controls, the majority were 
self-referrals.
One of the strengths in our study is the reliability of the patients’ diagnoses. Clinical and 
diagnostic assessment was made in accordance with the structured clinical interviews for 
DSM-IV criteria (SCID). Both SCID-I and SCID-II were used by trained professional clinical 
psychologists. In addition, to increase the inter-rater reliability, the rating was blindly 
repeated using the original audio taped interviews, by an external experienced and certified 
clinical psychologist who was unaware as to whether the participants where HC, MDD, or 
MDDA. All diagnoses were current.
Another strength is the exclusion of psychosis, bipolar, neurological disorders, drug/OTC/ 
alcohol-abuse and melancholic participants, characteristics that are associated with increased 
morbidity and hence impaired cognitive functions (Basso et al., 2007: Austin et al., 2001; 
Basso & Bornstein, 1999a; McCall & Dunn, 2003; Stordal et al., 2004).
Potential limitations regarding number of recurrent depressive episodes and age on onset for 
first depressive episode because they may be subject to information bias. This information 
was collected via self-report, and the specific age and number of episodes were at times 
difficult for the patients to pinpoint exactly. This may lead to misclassification in that the 
patients could be prone to both under- and over-estimating, thus resulting in inaccuracy 
regarding number and age. The heterogeneity of the anxiety disorders in our study may be 
both a strength in that it mirrors a clinical population that often exhibit a range of different 
anxiety disorders, but limits the results in that, even though the research on anxiety disorders 
have concentrated on few subtypes and therefore little is known about all subtypes, different 
anxiety disorders have shown to have different impact on cognitive functions. Therefore,
different combinations of diagnosis interactions between MDD and different anxiety subtypes 
may give different and specific neuropsychological deficits. Due to low numbers, no 
subdivisions were made of the anxiety disorders in our study.
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6.3.2. Possible confounding factors
The possible confounding factors age, gender, education level, general cognitive functioning 
(IQ estimate), depressive and anxiety symptom, level age of onset first depressive episode and 
number of recurrent depressive episodes were controlled for in the analyses. Some baseline
demographic variables differed between the groups: age, education level and general 
cognitive functioning (IQ). Nonetheless, education, age, number of depressive episodes, age 
of onset and gender failed to account for significant variance in the multivariate analyses of 
neuropsychological test performance. The MDDA and HC groups did not differ in age, but 
the MDD group differed significantly, the age being older than the HC group. Importantly,
the MDDA group did not differ in age from HC and the age being younger than the MDD 
group.
Estimating the general cognitive functioning (IQ) is an important confounding factor in the 
association between psychiatric disorders and neuropsychological functions (Lezak, 2004). 
Since, education level and general cognitive functioning correlated, we did not enter the latter 
in our analyses, but controlled for education level. Even if the MDDA group had significant 
lower mean regarding IQ than both HC and MDD, and lower education level than the HC 
group, the MDDA group still performed within the normal range.
Differences in estimated IQ between clinical and healthy control samples represents a 
theoretically and statistically challenge in general. To what extent these group differences is a 
result of sampling error or a difference accounted for by the diagnoses itself, is an important 
issue to address. That MDDA represents a more severe symptomatology, more psychosocial 
strain and in general reduction in many domains, may lead one to conclude that with this 
follow the reduction of general cognitive functioning. One possibility could have been to 
match the groups on IQ, but then important information about the MDDA group would have 
been lacking.
Possible effects of medication are also one confounding factor that must be addressed. The 
proportion of the patients in each of the two the clinical groups that were using SSRI/SNRI
may be considered fairly representative for the clinical population at large, with a larger 
proportion in the MDDA group, as expected. The proportion in the groups regarding use of 
SSRI/SNRI was MDD=13 out of 37 and MDDA=11 out of 24. There are however opposing 
views to whether medication have effects on cognitive test performance or not, and if un-
medicated patients show more impaired cognition that medicated patients (Den Hartog et al., 
2003). Some studies suggest that medication may enhance cognition in MDD (Fergusson at 
al., 2003), but that the effects on MDDA may be different than for MDD (Herrera-Guzmàn et 
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al., 2009). Other studies suggest that modern antidepressants do not have deleterious effects 
on cognitive test performance (Den Hartog et al., 2003). However, the proportion of subjects 
in each clinical group in our study currently on medication may be considered fairly 
representative of the clinical population of MDD and MDDA. Thus the significant results in 
our study should not be an artefact of medication.
Still, there may be many other factors that could potentially confound to the association 
between MDD, MDDA and neuropsychological functioning. To mention a few characteristics 
we did not control for: work status, sleep disturbances, motivation for the test situation, level 
of physical activity, personality traits and coping abilities. In addition, effects of severity and 
length of depressive disorders, combinations of different anxiety diagnoses in the MDDA 
group, patient subgrups regarding subtypes and duration of depression in both MDD and 
MDDA were also not controlled for. All these potentially confounding factors may exist
independently of depression and anxiety or MDDA, or as parts of vulnerability present which 
could also lead to poorer test performance.
6.3.3. Measurement and operationalizations of neuropsychological functions
In the current study, the neuropsychological tests were grouped in domains a priori; this was 
due to the hypothesis based on earlier findings. Still, the selection of which test used in the 
study is not unproblematic because many of the functions are closely related and traditionally 
the same tests have been used do measure the same functions. Furthermore, the considerable 
diversity of tests used in different studies also complicate the comparability of results
Also, intercorrelations (overlap) between constructs (dimensions) of neuropsychological 
function are substantial. In our study, we tried to minimize this by using tests that assess the 
subfunctions of the construct at hand, that is, to divide the constructs into the basic 
components that the theoretically and empirically based models are suggesting.
The construction of the test battery used in the papers are based on theory and research 
traditions, and that seek out to assess basic level attentional subfunctions based on Posner’s 
model (1990), to working memory functions according to Baddeley & Hitch’s (1986) model,
and last; executive control subfunctions with tests corresponding with Miyake et al’s. (2000) 
model.
The cognitive functions were operationalized into tests based on theoretical foundations in 
addition to traditional empirical based neuropsychological tests. The tests were both computer 
based and pen/paper-tests, culture free and representative for the functions we wanted to 
study. To use single tests to measure neuropsychological performance and create profiles, are 
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traditionally used in clinical practice to create cognitive profiles. The overlap of many of the 
dimensions/functions that these often broad tests measure may lower the reliability.
Theoretically, the operationalizations of the constructs in our study that are based on single 
tests that tap different variables, may lower the reliability, and cautions should be made when 
interpreting the results based on these single variables because confidence intervals often 
overlap. Another concern about this approach in this study is the risk of committing Type I 
error when multiple comparisons are performed. Results from the research literature are often 
based on analyses from many single tasks, and statistical significant results on one or few 
associations may then be subject to over-interpretation. To correct this, we performed 
Bonferroni corrections in all our analyses.
6.3.4. Statistics
In our study we corrected for multiple comparisons by post hoc adjustment with Bonferroni 
corrections to avoid Type I errors. The use of Bonferroni corrections in our study may be too 
conservative since we had a priori hypothesis concerning the difference between the two 
clinical groups, and between the clinical versus the healthy control group. We therefore 
performed a pairwise comparison without adjusting for the family-wise error rate between the 
two clinical groups regarding the dependent variables.
Most studies that investigate the difference between patients with psychiatric disorders and 
healthy controls with regards to neuropsychological functioning base their findings on 
significance testing. However, in significant testing the p-value do not provide the magnitude 
of difference between groups, in addition to that the differences in means between the groups
do not distinguish whether they apply to all participants in the groups or to subgroups within 
the groups. Even though there were no outliers that could explain the variance between the 
groups in our study, there could still be factors that testing of significance do not detect.
Due to relatively small sample sizes in our study, there is a risk for Type II errors, that is,
lower possibility of positive findings. That our study generated statistical significant 
differences between the groups on several variables, may be seen as strength for the results.
Importantly, statistical significance does not automatically imply clinical significance, and the 
results should be addressed accordingly.
6.4. Clinical implications
Many patients with diagnosable mood disorders have co-morbid anxiety, characterized by a 
severe and persistent clinical course that makes diagnosis and treatment challenging (Kuzel, 
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2005; Brown et al., 2005). Higher rates of healthcare use and costs are also associated with 
co-morbidity because these patients have more psychological, physical, and social impairment 
than those with either disorder alone (Kuzel, 2005; Brown et al., 2005). It is crucial for 
clinicians to recognize both anxiety and depression early in the clinical course and institute 
appropriate therapy aimed at making the patient well (i.e. achieving full remission) rather than 
merely improving symptoms. Patients with co-morbid anxiety and depression tend to 
discontinue treatment earlier than those with depression alone, and MDD accompanied by 
high levels of anxiety symptoms have been shown to be significantly less likely to benefit 
from anti-depressant medication of any kind (Fava et al., 2008) in addition to that they may
not respond as robustly to conventional treatments (Kuzel, 2005; Brown et al., 2005). The 
introduction of newer classes of antidepressants that exhibit both robust antidepressant and 
anxiolytic effects has provided the ability to treat both disorders with a single medication, and 
therefore it is vital to be aware of the high rate of patients that exhibit both disorders, and the 
effect this co-morbidity have on cognitive difficulties in their everyday lives (Howland & 
Thase, 2005). In addition, MDDA are more likely be unemployed, have less education, more 
severe depression, suicidal thoughts and in general more co-existing illnesses. Fava et al. 
(2008) states that “Clinicians should be aware of a patient`s sociodemographic situation and 
take note of co-occurring anxiety along with depression. The combination likely warrants a 
more personalized treatment approach”.
Neuropsychological functions, and hence neuropsychological testing of these functions has
clinical implications for the therapist and patient. It provides important additional information 
about daily functioning to adjust and fit the therapeutic process and goals according to the 
additional information about the individual patient’s neuropsychological functional profile 
and deficits. In addition, neuropsychological characteristics may be predictors of SSRI 
treatment response, where lowered level of functioning have been found in e.g. working 
memory and executive functions in non-responders to SSRI (Gorlyn et al., 2008).
6.5. Future perspectives
Future research should focus on examining the effects of co-morbidity between different 
subtypes of the depression spectrum and anxiety subtypes to examine whether there are 
specific combinations or subtypes that are moe prone to neuropsychological deficits than 
others. Whether effects of number of recurrent episodes, age of onset, family history,
eythymic phases or current diagnosis (state/trait), medication versus non-medicated patients,
and/or in/outpatients/population-based samples, are important issues to address to shed light 
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on the specific associations between these psychiatric disorders and neuropsychological 
functioning.
In addition, future studies should also undertake to specify the cognitive functions and 
corresponding tests, to help pinpoint the more basic underlying functions that may be the 
contributors to the higher level functions that are often seen impaired in both MDD and 
MDDA.
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7.0. CONCLUSIONS
7.1. Paper I
Patients with MDD displayed impairment in basic level attention subfunction Alerting, 
whereas MDDA showed specific impairments in top-down/higher level attentional functions.
7.2. Paper II
Both MDD and MDDA showed impaired WM, but MDDA performed significantly below 
MDD. Only MDDA displayed deficient verbal LTM.
7.3. Paper III
Patients with MDDA demonstrated selective deficits in the executive control functions;
Shifting and Updating, whereas MDD displayed psychomotor slowing.
In sum:
These findings imply that the presence of co-morbid anxiety disorders in MDD may be a risk 
for more severe neuropsychological dysfunction. This may in turn indicate higher morbidity, 
poorer response to medication and psychotherapy, poorer ability to manage daily living and 
activities such as work and hence impaired occupational status. 
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8.0. ERRATA
1.
Paper I and II: Method section, Participants: n= 165 shall be changed to n=153.
This error was due to not changing the number of healthy control participants we started with 
before we did a double-check and found that due to our exclusion criteria’s we had to exclude 
12 participants. Unfortunately we did not change this in the articles.
2.
Paper I:  In the Abstract, it states HC (n=92). This should be changed to n= 91, which is the 
correct number of HC participants.
3.
In paper I, Results section, first line, there shall be written three groups, not four groups as 
stated.
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Cognitive control functions in unipolar major depression with 
and without co-morbid anxiety disorder
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Background: Impaired cognitive control functions have been demonstrated in both major 
depression (MDD) and anxiety disorder (A), but few studies have systematically examined the 
impact of MDD with co-morbid A (MDDA), which is the main aim of this study. Method: We 
compared patients with MDD with (MDDA; n = 24) and without co-morbid A (n = 37) to a group 
of healthy controls (HC; n = 92) on three subtests from the Cambridge Neuropsychological Test 
Automated Battery; intra–extra dimensional, stop signal task, and spatial working memory. These 
tasks correspond to a theoretical model consisting of three separable but interrelated executive 
control functions: Shifting, Inhibition, and Updating. A simple psychomotor speed measure was 
also included. Results: After controlling for age, gender, and education level, the results showed 
that the MDDA group displayed signiﬁcantly impaired performance on the functions Shifting and 
Updating compared to HC. There emerged no signiﬁcant differences between any of the patient 
groups and HC regarding Inhibition. The pure MDD group did not display dysfunctions relative 
to the HC group on the main executive control variables, but displayed slowed psychomotor 
speed. Contrary to expectation there were no signiﬁcant differences between the MDDA and 
the MDD groups. Conclusion: Co-morbid anxiety should be taken into account when studying 
cognitive control functions in major depression.
Keywords: unipolar major depression, co-morbid anxiety disorder, cognitive control functions, CANTAB
2004; Levin et al., 2007; Porter et al., 2007 for reviews). The few stud-
ies distinguishing between unipolar and bipolar depressed patients 
have not displayed a consistent picture (Gruber et al., 2007 ) but 
impaired inhibitory control seem to be more pronounced in bipolar 
versus MDD patients.
Findings link cognitive control deﬁcits in MDD to increase in 
negative affect (McNeely et al., 2005; Dennis and Chen, 2007), a 
tendency to ruminate (Nolen-Hoeksema, 1991), increasing number 
of depressive episodes (Vanderhasselt and De Raedt, 2009), and a 
family history of depression in children (Perez-Edgar et al., 2006; 
Vanderhasselt and De Raedt, 2009).
Cognitive control embodies the ability to organize incoming 
stimuli and inhibit a dominant response in order to perform a 
subdominant response (MacLeod et al., 2002). However, executive 
functions are complex, and because they manifest themselves by 
operating on other cognitive processes, this implicates other cogni-
tive processes not directly relevant to the target executive function, 
hence “the task impurity problem” (Philips, 1997). Executive tasks 
have also tended to suffer from relatively low internal and/or test–
retest reliability (Denckla, 1996; Rabbit, 1997; Miyake et al., 2000), 
and widely used and accepted tests like, i.e., WCST and TOH have 
based their construct validity on loose criteria such as “sensitive 
to frontal lobe damage.” The complexity of the construct is also 
reﬂected in the myriad of terms and deﬁnitions used to charac-
terize executive control functions in addition to the tests used to 
measure them.
INTRODUCTION
Depressive disorders present a signiﬁcant mental health concern 
to individuals and to our society. It is estimated that mood disor-
ders will be the most frequent cause of serious health problems 
worldwide in 2020 (WHO). The lifetime risk for major depressive 
disorder (MDD) is between 10 and 25% for women and between 
5 and 12% for men (American Psychiatric Association, 1994).
Affective neuroscience research has been increasingly focus-
ing on cognitive or executive control processes (for a review, see 
Ochsner and Gross, 2005). Investigations of executive control func-
tions are in general relevant across a range of psychiatric disorders, 
like schizophrenia (Wilmsmeier et al., 2010), obsessive compulsive 
disorder (Olley et al., 2007), and bipolar disorder (Daban et al., 
2006). Although these disorders share a common deﬁcit in execu-
tive functions, a main issue is to what degree there are differences 
and similarities along various dimensions of executive functions 
across such disorders.
Retarded psychomotor speed, as measured by simple reaction 
time tests, was traditionally considered a basic clinical character-
istic of unipolar MDD. Although slowed reactions obviously are 
a relevant aspect of the neuropsychological proﬁle in depression 
(Egeland et al., 2005), associated cognitive dysfunctions cover a 
broad range (Burt et al., 1995; Christensen et al., 1997; Kindermann 
and Brown, 1997; Veiel, 1997; Austin et al., 2001; Landrø et al., 2001; 
Porter et al., 2007). Impaired executive cognitive control functions 
seems to be particularly salient (Austin et al., 2001; Rogers et al., 
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the assessment of neuropsychological status (RBANS) in relation 
to the pure depression group. They found no relevant differences in 
mean scores for the depressed group in the study and the depressed 
group in the RBANS validation study. However, the inclusion of a 
healthy control group would give an indication of how the clinical 
groups differ compared to a healthy population.
On the other hand, in a review Levin et al. (2007) states that 
when the noise introduced by unassessed co-morbid anxiety is 
successfully addressed, executive function impairments speciﬁc to 
depression can account for many of the cognitive deﬁcits identi-
ﬁed. Similarly, within the context of a population based sample it 
was found that the subgroups of MDD and MDD with co-morbid 
Axis I disorder did not differ on any of the cognitive measures 
assessed, and conclude that psychiatric co-morbidity may not 
aggravate cognitive functioning among depressed young adults 
(Castaneda et al., 2009).
While a substantial number of patients with MDD have co-
morbid anxiety that possibly contributes to cognitive impairments, 
most patients with MDD also experience recurrent episodes. 
Research on the possible effects of number of episodes on cogni-
tion has yielded inconsistent results regarding whether number of 
recurrent depressive episodes confounds with increased cognitive 
impairment or not (Veiel, 1997; Basso and Bornstein, 1999; Stordal 
et al., 2004). In light of the previous limited research, inconsistent 
results and clinical importance, there is a vital need for further 
research to address these issues.
Although a considerable body of research documents that chil-
dren of depressed parents exhibit higher rates of mood disorders 
than comparison groups (see Klimes-Dougan et al., 2006), there 
are only a few studies that have been directed toward examining 
neurocognitive functioning in this risk group. One of few studies 
that examined family history and executive functions is Klimes-
Dougan et al. (2006) who studied neuropsychological function-
ing in offspring of parents with a history of mood disorders and 
found deﬁcits in, e.g., executive functioning in BPD offspring 
compared to offspring of well mothers. Deﬁcits were not found 
for children of MDD mothers. Still, heritability is estimated as 
high as 70%. Characteristics that have generally been shown to 
predict a larger increase in risk to their relatives are, e.g., recurrent 
episodes (Sullivan et al., 2000) and earlier age at onset (see review 
by Levinson et al., 2003).
The main aim of this study was to investigate basic components 
of cognitive control functions in patients with MDD with or with-
out co-morbid anxiety disorders, and compare to a healthy control 
group. Consistent with prior research regarding neurocognition 
in affective disorders, we expected both patient groups to perform 
worse than the HC, but that the MDDA group would perform 
worse than the MDD without anxiety. Possible effect of number of 
depressive episodes and age of onset ﬁrst depressive episode was 
also investigated.
MATERIALS AND METHODS
The study was approved by the Regional Committee for Medical 
Research Ethics, Norwegian Social Science Data Services (NSD) 
and adhered to the Helsinki Convention.
Written informed consent was obtained after the participants 
had been provided with a complete description of the study.
In an attempt to minimize the task impurity problem, Miyake 
et al. (2000) used latent variable analysis to determine to what 
extent different executive processes can be considered to be uni-
tary (in the sense that they are reﬂections of the same underlying 
mechanism or ability) or non-unitary. They focused on the fol-
lowing three basic executive functions: (1) shifting between tasks 
or mental sets, (2) inhibition of dominant or prepotent responses, 
and (3) updating and monitoring the contents of working memory. 
Conﬁrmatory factor analysis indicated that these three executive 
processes, although moderately correlated with one another, are 
clearly separable. The model proposes relatively circumscribed 
lower (basic) level functions compared to many of the wider and 
higher level deﬁnitions and general measures of executive function-
ing, thus allowing precision as to which cognitive control functions 
are affected and which are not. However, neuropsychological studies 
of mood disorders based on an empirically based model of basic 
executive control functions are relatively sparse.
There is extensive co-morbidity between MDD and other 
affective disorders, especially anxiety disorders (A), regarding 
phenomenological features as well as neuropsychological function-
ing. Individuals with depression and co-morbid anxiety disorders 
occur in from 25 to 60% of cases, and are associated with increased 
severity, greater chronicity, slower recovery, increased rates of recur-
rence, greater risk for suicide, and greater psychosocial disability 
(Cameron et al., 2004; Leonardo and Hen, 2006).
Anxiety can potentially confound or contribute to neuropsycho-
logical impairments or anatomic changes in depressed individuals 
(Cameron et al., 2004; Leonardo and Hen, 2006), and is in general 
associated with heightened distractibility, poor concentration, and 
increased responsivity to potential threat (Bishop et al., 2004b). 
Several studies have demonstrated neuropsychological deﬁcits 
involving, i.e., executive function, attention, working memory, and 
attentional control to threat-related stimuli in anxiety disorders 
(Broadbent et al., 1986; Asmundson et al., 1994; Cohen et al., 1996; 
Vasterling et al., 2000; Lautenbacher et al., 2002; Danckwerts and 
Leathem, 2003; Ludewig et al., 2003; Bishop et al., 2004b; Basso et al., 
2007). The latter have been demonstrated with emotional Stroop 
(Mathews et al., 1997) and associated with deﬁcits that are particular 
to the execution of attentional inhibition (Fox, 1994). This impaired 
cognitive control over threat-related distractors has also been sup-
ported by fMRI studies (Bishop et al., 2004a).
The effects of co-morbid anxiety in MDD have been systemati-
cally investigated in only a few studies. It has been suggested that 
executive dysfunction and psychomotor slowing are speciﬁc to the 
depressed group with co-morbid anxiety (Basso et al., 2007). The 
latter group also displayed more impaired scores than both “pure” 
MDD and HC. The limitations of this study are mainly the reliabil-
ity of patient diagnoses; the data were collected retrospectively from 
available records, and the diagnoses lacked a structural diagnostic 
interview. The patient sample also consisted entirely of inpatients, 
and the literature suggests that inpatients are more severely impaired 
than outpatients (Burt et al., 1995; Christensen et al., 1997; Veiel, 
1997). Corroborating these results, a recent study concluded that 
the strongest predictor of poor cognitive performance in depression 
was psychiatric co-morbidity (Baune et al., 2009). The co-morbid 
group showed decreased cognitive performance in visuospatial and 
language domains and in total score on the repeatable battery for 
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The Beck Depression Inventory (BDI-II; Beck et al., 1961) and 
The Beck Anxiety Inventory (BAI; Beck and Steer, 1988) were ﬁlled 
out by the participants to measure severity of depression and anxi-
ety symptoms. General level of functioning were screened using 
Global Assessment of Functions Scale for symptom and function 
(GAF-S and GAF-F; DSM-IV).
General medical and psychiatric background, demographic 
information, past episodes of recurrent major depression and family 
medical and psychiatric history were obtained using a semi-struc-
tured interview developed by the ﬁrst author (Lyche, 2006) based 
on the diagnostic interview for genetic studies (DIGS; Nurnberger 
et al., 1994) and a semi-structured screening instrument developed 
by Biringer (2005), University of Bergen. Education level was clas-
siﬁed by means of The International Standard Classiﬁcation of 
Education (ISCED; UNESCO, 1997).
GENERAL COGNITIVE MEASURES
General cognitive functioning was estimated from the mean of 
two subtests from the WAIS-III: picture completion (PC) and-
similarities (SI) (Wechsler, 1999).
NEUROPSYCHOLOGICAL ASSESSMENT
Three subtests from the Cambridge Neuropsychological Test 
Automated Battery (CANTAB) which measure executive control 
functions according to Miyake et al. (2000) model were adminis-
tered. In addition; a motor screening test (MOT) was administered 
in the beginning of the test session.
The neuropsychological tests were administered by a clinical 
psychologist trained in standardized assessment, or by an experi-
enced test technician.
Cambridge Neuropsychological Test Automated Battery
The Cambridge Neuropsychological Test Automated Battery 
(CANTAB, 2006) is comprised of computerized neuropsycho-
logical tests that examine various areas of cognitive function. The 
CANTAB tests are simple, computerized, non-linguistic and cultur-
ally blind, and allow us to break down executive control functions 
into cognitive components in order to deﬁne more readily which 
functions are impaired or spared. Three subtests were used in this 
study; intra–extra dimensional (ID/ED), spatial working memory 
(SWM), and stop signal task (SST), which correspond to the three 
functional areas according to Miyake et al. (2000) non-unitary 
model of executive functions.
Shifting. The ID/ED set-shift task is a test of rule acquisition and 
reversal. The task assesses the ability to maintain attention to different 
examples within a stimulus dimension (ID stages), and the ability 
to shift attention to a previously irrelevant stimulus dimension (ED 
shifts) across nine stages. Subjects proceed to the next stage when a 
criterion of six consecutive correct responses has been reached.
The two performance variables of interest are the number of 
stages completed, and the total error score adjusted for whether 
the entire task is completed (Kaplan et al., 2006).
Inhibition. The SST is a classic stop signal response inhibition test 
(Logan et al., 1984, 1997; Osman et al., 1986). It uses staircase func-
tions to generate an estimate of stop signal reaction time. The test gives 
PARTICIPANTS
A total of 165 subjects were included in the study. From this sample, 
61 fulﬁlled the criteria for current primary non-psychotic unipo-
lar major depression (MDD), according to the Structured Clinical 
Interview for Diagnostic and Statistical Manual of Mental Disorders 
for Axis I (DSM-IV; APA, 1994). Of these 24 subjects fulﬁlled the 
MDD criteria with co-morbid anxiety disorder, whereas 37 had no 
co-morbid anxiety disorder.
The distribution of the anxiety subtypes for the MDDA group 
was: GAD = 3, SP = 13, OCD = 4, PTSD = 2, panic with agora-
phobia = 6, panic without agoraphobia = 4, speciﬁc phobia = 3, 
anxiety NOS = 2. Fourteen patients had one anxiety diagnosis, and 
10 patients had two or three anxiety disorders.
The proportion of patients medicated in each group was: MDD 
(SSRI = 12, SNRI = 1) and MDDA (SSRI = 9, SNRI = 2). In the 
MDD group, 24 were unmedicated and there were 13 unmedicated 
in the MDDA group. The HC group was unmedicated.
The number of depressive episodes was distributed as follows 
for the MDD group: 1 episode (the current one) = 20, 2 = 5, 3 = 3, 
4 = 2, 5 = 2, 6 = 1, 10 = 2, 40 = 2. For the MDDA group: 1 episode 
(the current one) = 12, 2 = 3, 3 = 2, 4 = 1, 6 = 1, 10 = 1, 15 = 1, 
above 50 episodes = 3. The MDD group had one with dysthymia 
(i.e., “double-depression”), and the MDDA group had 2 with dys-
thymia (i.e., “double-depression”). All the subjects in the MDD and 
MDDA group had a non-melancholic subtype. The distribution 
of family history of depression versus no history, were as follows: 
HC (77/15), MDD (4/33), and MDDA (6/18).
The patients were recruited from psychiatric clinics for out-
patients in the Oslo and Trondheim area. Inclusion criteria 
were: to be fluent in Norwegian, and to be taking no medica-
tion other than SSRI/SNRI. The subjects were required to be 
medication-fasting the day of testing. General exclusion crite-
ria were: a history of neurological disorders, bipolar, psycho-
sis, drug/alcohol-abuse including non-prescription OTC drugs. 
Two participants were excluded due to scaled score b4 on the 
Wechsler Adult Intelligence Scale Third edition (WAIS-III) 
subtest Similarities. For comparison, 91 healthy controls (HC) 
were selected from an original sample of 125 subjects. They 
were recruited via newspaper ads, posters and through vari-
ous private companies in the Oslo region. They were screened 
for psychopathology using SCID-I and SCID-II. Thirty-three 
subjects were excluded from the original sample of 125 due to 
the following criteria: brain injury exceeding 30 min. loss of 
consciousness (n = 2), BDI r 10 (n = 9), weekly alcohol intake 
15 IU (n = 1), daily use of drugs (n = 1), and personality dis-
order (according to DSM-IV; SCID-II; n = 2). Furthermore, 18 
participants were excluded who had had one or more depressive 
episodes in the past.
CLINICAL EVALUATION
Clinical and diagnostic assessment was made in accordance with 
the structured clinical interviews for DSM-IV criteria (SCID). Both 
SCID-I and SCID-II were used by trained professional clinical psy-
chologists. In addition, the rating was blindly repeated using the 
original audio taped interviews, by an external experienced clinical 
psychologist who was unaware as to whether the participants where 
HC, MDD, or MDDA (validated by one of the co-authors: TCS).
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Differences between the groups were found regarding age 
[F(2, 152) = 6.637, p  0.01], education level (ISCED) [F(2, 
152) = 9.67, p  0.001], and general cognitive functioning (WAIS-
MEAN) [F(2, 152) = 14.055, p  0.001]. There were no signifi-
cant differences between MDD and MDDA on BDI, but MDDA 
had a higher score on BAI than MDD [F(2, 151) = 115.259, 
p  0.001].
There were no signiﬁcant between-group differences in terms 
of gender [C2 (2) = 1.85, p = 0.397] distribution and handedness 
[C2 (4) = 8.60, p = 0.072].
The patients with MDD differed signiﬁcantly from the HC group 
regarding age, the mean age being older for MDD. The MDDA 
group differed signiﬁcantly from the MDD group, the mean age 
being younger for the former. There were no statistical differences 
in age between MDDA and HC.
According to estimated general cognitive functioning, the 
MDDA group had signiﬁcantly lower mean than HC and MDD. 
The MDDA differed signiﬁcantly from the HC group regarding 
education level, the former having lower mean ISCED-level.
Since educational level and estimated general cognitive 
functioning was correlated we did not enter the latter in the 
MANCOVA.
a measure of an individual’s ability to inhibit a prepotent response. 
The term “response inhibition” refers to cognitive processes enabling 
executive control over prepotent responses in accordance with chang-
ing situational demands. The main outcome variable of interest for 
our purpose is the stop signal reaction time (SSRT), which is an esti-
mate of the subject’s response time to the stop signal, i.e., the time it 
takes to react to the stop signal by inhibiting the prepotent response 
to the go signal (i.e., the time required to inhibit a response after it 
has been initiated). SSRT is estimated by subtracting stop signal delay 
(SSD) from mean Go signal reaction time (RTonGT).
Updating. Spatial working memory is a test of the subject’s ability 
to retain spatial information and to manipulate remembered items 
in working memory. It is a self-ordered task which requires sub-
jects to search for hidden “tokens” within a spatial array of colored 
boxes. By touching the boxes and using a process of elimination, 
the subject should ﬁnd one blue “token” in each of a number of 
boxes, and then use them to ﬁll up an empty column on the right 
hand side of the screen. The number of boxes is gradually increased 
until it is necessary to search a total of eight boxes. The color and 
position of the boxes used are changed from trial to trial in order to 
discourage the use of stereotyped search strategies. The rationale for 
this task and its implementation has been described previously in 
some detail (Owen et al., 1990). Outcome measures of interest are 
a “between” errors score, which is calculated when a subject returns 
to a square where a token was already found in a previous trial. This 
assesses the accuracy of working memory, as a strategy measure is 
derived; i.e., a subject’s ability to adopt a systematic search strategy: 
a lower strategy score reﬂects more efﬁcient task performance on 
SWM (Owen et al., 1990; Weiland-Fiedler et al., 2004).
PSYCHOMOTOR SPEED
In addition to the main variable of inhibition on the SST task, an 
outcome measure of reaction time on Go trials (GoRT), an indica-
tor of psychomotor speed, was included.
DATA ANALYSIS
Data analysis was completed by means of SPSS version 16.0 
(SPSS Inc., Chicago, IL, USA). Multivariate analysis of covariance 
(MANCOVA) was ﬁrst used to compare the patient groups (MDD 
and MDDA) and the HC on the combined score of the six depend-
ent variables measured at the individual level: ID/ED stages com-
pleted, ID/ED total errors adjusted, SWM strategy, SWM between 
errors, SST RT on Go trials, and SST SSRT, while simultaneously 
controlling for age, sex, and education level. Follow-up univariate 
analysis of covariance (ANCOVA) was then performed to detect 
which of the six dependent variables the three groups differed sig-
niﬁcantly from each other in mean scores. Finally, ANCOVA was 
also used to compare the MDD group and the MDDA group on 
the six dependent variables controlling for the number of earlier 
depressive episodes and age of onset of ﬁrst depressive episode.
RESULTS
A series of one-way analyses of variance (ANOVAs) and Chi-square 
tests was conducted to compare the four groups across the demo-
graphic variables, followed by post hoc tests with Bonferroni cor-
rections to determine which groups differed (Table 1).
Table 1 | Descriptive statistics for demographic variables, clinical 
characteristics, and general cognitive functioning (estimated from the 
WAIS-III subtests Similarities and Picture Completion) for patients with 
MDD, MDDA, and healthy comparison subjects.
   Healthy 
 MDD (n = 37) MDDA (n = 24) controls 
   (n = 91)
 M SD M SD M SD
Age (years) 44.2 12.3 35.5 14.2 35.8 12.0
Education (years) 15.8 3.2 13.5 2.3 16.4 2.5
BDI 21.4 11.1 25.4 7.4 2.1 2.7
BAI 11.6 8.2 18.7 6.7 2.1 2.5
Symptom-GAF 60.2 12.1 53.8 8.5 95.6 7.3
Function-GAF 63.6 13.8 55.2 10.1 96.7 5.6
General cognitive  11.1 2.1 9.3 2.6 12.1 2.4 
functioning
Age of onset ﬁrst 33.5 14.4 30.1 16.1   
MDD episode
 n % n % n %
GENDER
 Male 14 37.8 11 45.8 28 30.7
 Female 23 62.2 13 54.2 63 69.3
HANDEDNESS      
 Right 35 94.6 24 100 8 42.1
 Left 1 2.7 0 0 11 57.9
Ambidextrous 1 2.7 0 0 0 0
MDD, current major depressive disorder; BDI, Beck depression inventory; 
BAI, Beck anxiety inventory; GAF, global assessment of functioning axis-V 
in Diagnostic and statistical manual of mental disorders – Fourth Edition 
(DSM-IV).
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the dependent variables: ID/ED total errors adjusted and SWM 
between errors. The MDDA group performed the tasks with more 
errors than the HC.
There were signiﬁcant differences between the MDD group and 
the HC group on SST RT on Go Trials. MDD performed the task 
with slower psychomotor speed compared to the HC group. There 
were no statistical signiﬁcant differences between the clinical groups 
on any of the other variables.
The results and mean scores for each group are presented in 
Table 2. Proﬁles of the three groups on the CANTAB variables are 
presented in Figure 1.
Although there was a signiﬁcant difference between the MDDA 
group and HC on the general cognitive measure, the patients nev-
ertheless performed well within the normal range. As compared to 
the formal norms the performance level equals less than one-third 
SD from the mean.
The MANCOVA demonstrated a signiﬁcant overall group dif-
ference in performance on the CANTAB tests [F(12, 284) = 2370, 
p  0.01] Follow-up ANCOVAs and post hoc tests demonstrated 
that after controlling for gender, age, and education level and 
adjusted for multiple comparisons (Bonferroni), there were sig-
niﬁcant differences between the MDDA group and HC on two of 
Table 2 | Neuropsychological test performance on the CANTAB variables for patients with MDD, MDDA, and healthy comparison subjects (HC). 
Difference in mean scores is controlled for age, gender, and education level.
 MDD (n = 37) MDDA (n = 24) Healthy controls(n = 91) Statistical analyses ANCOVA
 M SD M SD M SD F df p
SET-SHIFT
 ID/ED; stages completed 8.4 1.6 8.3 0.9 8.7 0.7 1.399 2 0.250
 ID/ED; total errors adj. 25.8 19.4 33.0 22.0 20.4 18.0 4.255 2 0.016*
WORKING MEMORY/UPDATING
 SWM; between errors 25.1 17.9 27.8 18.1 16.3 15.1 4.658 2 0.011*
 SWM; strategy 32.3 6.0 33.1 5.4 30.8 6.0 1.764 2 0.175
INHIBITION
 SST; SSRT last half 189.1 64.9 202.5 74.5 180.1 50.4 1.785 2 0.171
RT/PSYCHOMOTOR SPEED
 SST; RT on GO trials 506.1 140.8 412.3 82.7 407.7 123.7 3.701 2 0.027*
*p  0.05.
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FIGURE 1 | Proﬁles for the three groups on the six CANTAB variables (z-scores).
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WM in depression and anxiety represent symptom or syndrome 
factors, or an interaction of both with situational stress as a medi-
ating factor (Eysenck and Calvo, 1992; Chong, 2003; Murray and 
Janelle, 2003).
The ID/ED results indicate that the MDDA group showed more 
total errors and thus were less able than HC to learn to shift or 
switch attention to new previously irrelevant exemplars of stimuli 
or mental sets. Symptom severity on BAI, but not BDI, showed a 
signiﬁcant correlation with set shifting. This indicates that self-
reported anxiety symptom severity and the set-shift function are 
linked in the MDDA group; this relates to the speciﬁc roles of 
symptom and syndrome anxiety in executive control functions.
In contrast to Basso et al. (2007), we found no signiﬁcant psycho-
motor slowing in the MDDA group. However, in the MDD group 
showed reduced psychomotor speed compared to HC. The research 
ﬁeld has published frequent ﬁndings of psychomotor slowing in 
both MDD and in MDDA, but to our knowledge only a few stud-
ies (Dutke and Stöber, 2001) have found more rapid psychomo-
tor speed in anxiety. There are numerous theories stating that the 
presence of anxiety yields slower processing due to an obsessive 
or ruminative approach to testing (Basso et al., 2007). Moreover, 
the proﬁle and nature of cognitive dysfunction is hypothesized to 
depend upon anxiety subtype, and the majority of studies have 
focused mainly on OCD.
Anxiety patients often exhibit a fear of new or unfamiliar situa-
tions. Therefore the experimental situation itself is often sufﬁciently 
threatening to arouse a signiﬁcantly greater amount of manifest 
anxiety in the anxiety group than in than the other two groups with 
depression. One may wonder if this creates a drive or motivation 
that can be measured as increased psychomotor speed. It may be 
hypothesized that in this study, it is the depression component that 
contributes to the deﬁcits in speed, and that the lack of psycho-
motor deﬁcit in the MDDA group was due to counterbalance by 
two inverse tendencies, or to a competition between psychomotor 
retardation and “acceleration.”
Number of earlier depressive episodes in the MDD and MDDA 
group was not signiﬁcantly associated with the dependent variables. 
This result contradicts research ﬁndings where number of depres-
sive episodes seems to have a cumulative effect on cognitive control 
impairment in MDD (Vanderhasselt and De Raedt, 2009). One of 
the main hypotheses is that each repeated depressive episode “leaves 
a mark” in the brain (Sheline, 2000). Stordal et al. (2005) found 
no impairment in executive functions in about half the patients 
with recurrent MDD, although the depressed patients with execu-
tive function impairments were the ones with more episodes than 
the patients without such impairments. In line with our present 
results, other studies have found no association between number 
of episodes and performance on tests that tap executive functions 
(Reischies and Neu, 2000; Grant et al., 2001).
Regarding the notion that the MDDA group represents an addi-
tive effect in severity, studies by Purcell et al. (1997), Elliott et al. 
(1996), and Beats et al. (1996) show that both inpatients with a 
more severe history of depression and hospitalization, and eld-
erly patients may exhibit more evident set-shift deﬁcits than do 
younger/middle-aged outpatients (Purcell et al., 1997). One reason 
why the research ﬁeld has yielded different results may be that 
to our knowledge, the previous research concerning MDD with 
Furthermore, we performed two ANCOVAs to test whether there 
was a difference between the two mood disorder patient groups 
(MDD and MDDA) on the CANTAB variables when we controlled 
for the number of depressive episodes and age of onset ﬁrst depres-
sive episode. (There are nine missing in the MDD group and four 
missing in the MDDA group due to difﬁculties in gaining accurate 
information about age of onset from these subjects).
The results showed that the number of episodes and age of onset 
was not signiﬁcantly related to the dependent variables. Hence, 
including number of depressive episodes and age of onset as cov-
ariates in the analyses, did not alter the results, i.e., there were no 
signiﬁcant differences in mean scores on the dependent variables 
between the two groups.
A signiﬁcant Pearson correlation was found for the MDDA 
group between BAI and ID/ED; total errors adjusted (r = 0.48, 
p  0.05). There were no signiﬁcant correlations for the SWM; 
between errors. No signiﬁcant correlations were found between 
BDI and the two CANTAB measures.
DISCUSSION
The current data indicate that signiﬁcant neuropsychological 
impairment in cognitive control functions corresponds with the 
presence of MDD and co-morbid anxiety. The MDDA group dis-
played signiﬁcantly impaired performance with respect to working 
memory and set shifting compared to the HC. The MDD group did 
not show cognitive control dysfunctions relative to the HC, except 
for displaying slowed psychomotor speed. Contrary to expectation 
the MDDA group did not perform worse than the MDD group. 
There emerged no signiﬁcant differences between any of the clini-
cal groups and HC on the ability to inhibit a prepotent response. 
Number of depressive episodes and age of onset for ﬁrst depressive 
episode was not signiﬁcantly related to either working memory or 
set shifting test performance.
The MDDA group displayed impairment in relation to the HC 
group on the variable assessing updating in working memory. This 
is an error score, and not the variable assessing the ability to adopt 
a systematic strategy. This indicates that it is the “pure” working 
memory that is affected. This is in concert with general theories 
of affect–cognition interactions, stating that anxiety impacts cog-
nitive load by the depletion of central executive resources, i.e., 
restrictions in WM capacity (Eysenck and Calvo, 1992; Shackman 
et al., 2006).
Negative mood and rumination require generally more atten-
tion than neutral and positive stimuli (Dolcos and McCarthy, 
2006; Van Dillen and Koole, 2007). Strong negative stimuli (as in 
major depression) may trigger more mood-congruent processing 
and thus employ more WM capacity. This interactive relationship 
between WM load and emotional intensity of negative stimuli were 
examined by Van Dillen and Koole (2007). Participants reported 
attenuated negative moods in WM trials with high demands, sug-
gesting that negative mood and WM capacity interact. Since we 
found no signiﬁcant correlation between symptom severity (BAI 
or BDI) for the MDDA group on the working memory variable, 
this may indicate that it is the diagnostic validity of the clinical 
ratings of syndrome MDD and co-morbid anxiety disorder that 
is reﬂected in the WM impairment. This adds data to the ongoing 
discussion and research about whether cognitive dysfunctions in 
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APPENDIX 1
BAKGRUNNSINFORMASJON
Instruksjon: Sett kryss ved rett svaralternativ eller fyll ut ledig plass
Dato for intervjuet:
Forsøksperson nr:
Intervjuer:
Henvist fra:
Demografi
Kjønn 1. Mann 
2. Kvinne 
Alder ________________
Dominant hånd 1. Høyrehendt 
2. Venstrehendt 
Sivil status 1. Gift/samboer 
2. Skilt/separert 
3. Singel/ugift 
4. Enke/enkemann 
Barn Ja  Nei  Hvis, ja: antall____________
Fullført utdanning (ISCED; 1997):
Hvor mange år har du gått på skole?:___________________________
Utdanningsnivå. Kryss av:
1. 6-årig grunnskole eller mindre
2. Grunnskole 7-9-år
3. Videregående skole 10-12 år: (teknisk/VK1/VK2 og 3/voksenopplæring) 
antall år:__________________
(Ikke akademisk utdanning dvs. som ikke krever artium eller lignende kodes under pkt 3.)
4. Påbegynt postgymnasial utdanning/ voksenopplæring
antall år:_____________
5. a) Fullført inntil Bachelor/Cand.Mag:
antall år:____________________ 
b) eller distriksthøyskolegrad/lærerutdanning:
antall år:______________________
6. Fullført Embedseksamen/Master/Hovedfag: _______________________
7.         Fullført doktorgrad
Utdanningsfelt:______________________________________________________________
___________________________________________________________________________
Hvis ufullstendig studium, hvorfor gjorde du deg ikke 
ferdig?_____________________________________________________________________
___________________________________________________________________________
Arbeid 1. Fast arbeid  Angi prosentandel:______
2. Student 
3. Arbeidssøker 
4. Trygd/sykemeldt/attføring
5. Ingen inntekt 
Smerter 
(Dette arket bør fylles ut av forsøksperson)
1. Har du kroppslige smerter som har vart mer enn 6 måneder? (Sett ring rundt svaret)
Ja          Nei  
2. Hvor sterke kroppslige smerter har du hatt i løpet av de siste 4 ukene? (Sett ring rundt 
svaret)
Ingen Meget svake Svake Moderate Sterke         Meget sterke
3. Hvor mye smerter har du nå? (Sett ring rundt svaret)
Ingen Meget svake Svake Moderate Sterke         Meget sterke
Trettbarhet : PRE-testing
Hvordan vil du beskrive ditt nåværende nivå av generell trettbarhet? 
(eks. nedsatt energi fysisk og psykisk, utmattelse)
Ingen Meget svakt Svakt Moderat Sterkt      Meget sterkt
Somatisk sykdom
Har du hatt noen somatiske sykdommer? (Oppgi starttidspunkt og varighet)
(Eks. Stoffskiftesykdommer, Organisk hjernesykdom (epilepsi, migrene, nevrologisk etc.), 
Sykemeldinger, Familiære sykdommer/opphopning)
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
Skader
Har du hatt hjernerystelse/hodeskader? (Oppgi antall ganger og hvilke skader)
Hvis ja: antall ganger________________________
Var du bevisstløs i sammenheng med dette?
Bevisstløshet (min, timer, mnd, år):________________________
Har du hatt andre skader som benbrudd etc? (Hvilke, antall ganger)
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
Psykisk sykdom Oppgi debuttidspunkt og varighet
 Tidligere lidelser og nåværende
 Komorbiditet
 Innleggelser psykiatrisk institusjoner
 Familiære lidelser (1. gradsslektninger)
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
Sosiale endringer det siste året:
(Eks. Skilsmisse, Død i familie eller nær vennekrets, Mistet arbeid, Ulykker)
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
Stressende livshendelser/påkjenninger  i løpet av livet:
(Eks. Skilsmisse, Død i familie eller nær vennekrets, Mistet arbeid, Ulykker)
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
Tidligere medikamentell behandling:  
Medisiner (Tidsrom, type preparat og varighet)
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
Nåværende medikamentell behandling (tidsrom, type preparat og antatt varighet 
behandling, seponering) 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
Behandling:
 Samtaleterapi (individuell/gruppe) 
 ECT | 
(Eksklusjon: mindre enn 3 mnd siden ECT)
 Annet 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
Utredning:
 EEG/PET/CAT/MRI 
 Nevropsykologisk utredning 
 Nevrologisk utredning 
 Annet:________________________________________________________________
_____________________________________________________________________
 Sigaretter
Røyker  Røyker ikke 
Depresjonsutvikling/historikk:
Hvor gammel var du ved første gangs kontakt med psykiatrisk poliklinikk, 
privatpraktiserende psykolog/psykiater eller primærhelsetjeneste i forbindelse med psykiske 
plager/vansker?
Debutalder (ca): ______________
Hvor mange ganger har du vært deprimert mesteparten av dagen i over to uker av gangen?
Antall ganger (ca):_____________
Har du hatt regelmessig psykoterapi/gruppepsykoterapi tidligere?
(regelmessig er her minst 1 gang per uke i mer enn 3 mnd)
Ja 
Nei 
Hvis ja: hvor mange behandlingsperioder?______________________
Har du tidligere vært innlagt ved psykiatrisk døgnavdeling?
Ja 
Nei 
Hvis ja: antall ganger?_______________________________________
Depresjonsutvikling i løpet av livet:
DEPRESJON VARIGHET 
(mnd)
Innleggelser 
under episoden
Medikamentell 
behandling
Sykemeldinger
1. episode Ja /  Nei Ja /  Nei Ja /  Nei
2. episode Ja /  Nei Ja /  Nei Ja /  Nei
3. episode Ja /  Nei Ja /  Nei Ja /  Nei
4. episode Ja /  Nei Ja /  Nei Ja /  Nei
5. episode Ja /  Nei Ja /  Nei Ja /  Nei
6. episode Ja /  Nei Ja /  Nei Ja /  Nei
Sum: Sum: Sum: Sum: Sum:
Ble du frisk av depresjonen mellom episodene?
___________________________________________________________________________
Hvis ja, var du frisk i mer enn to måneder?
___________________________________________________________________________
___________________________________________________________________________
Dersom JA ved ett eller flere punkt i tabellen, oppgi:
Varighet av innleggelsen (oppgi antall dager):
ved episode 1: __________dager
ved episode 2:___________dager
ved episode 3: __________dager
ved episode 4:___________dager
evt. ved episode 5, 6, 7 osv.
Varighet av medikamentell behandling relatert til depresjonsepisodene (oppgi antall 
mnd):
ved episode 1:__________dager
ved episode 2:__________dager
ved episode 3:__________dager
ved episode 4:__________dager
evt. ved episode 5, 6, 7osv.
Varighet av sykemelding eller manglende evne til å studere/arbeide på grunn av 
depresjonsrelaterte plager (oppgi antall uker):
ved episode 1: ___________uker
ved episode 2: ___________uker
ved episode 3: ___________uker
ved episode 4: ___________uker
evt. ved episode 5, 6, 7 osv.
SCID-1 Versjon 2.0 (for DSM-IV) (Jan 1995 endelig) Silingsspørsmål  Siling  - Sid
SCID SILINGSMODUL
Nå vil jeg stille deg noen mer konkrete 
spørsmål om problemer du kan ha oppleved. 
Vi skal se på disse mer detaljert siden.
BESVAR BEKEFTENDE SVAR MED: Vi skal snakke mer om det siden.
Har du noen gang i løpet av ditt liv drukket fem eller flere drinker 1   2
3 P1
(øl, vin eller sprit) ved en og samme anledning?
Har du noensinne brukt ulovlige narkotiske stoffer? 1   2
3 P2
Har du noensinne blitt ”hekta” på en reseptmedisin eller tatt 1   2
3 P3
mer av det enn du skulle?
Har du noensinne hatt et panikkanfall hvor du plutselig 1   2
3 P4
følte deg skremt eller engstelig eller plutselig utviklet en
rekke fysiske symptomer?
Har du noensinne vært redd for å forlate huset alene, være 1   2
3 P5
i folkemengder, stå i kø eller for å reise med buss eller tog?
Er det enkelte ting du var redd for å gjøre eller følte deg 1   2
3 P6
ubekvem når du gjorde foran andre folk, som f.eks å snakke
spise eller skrive?
RING RUNDT
”NEI” PÅ E. 10
RING RUNDT
”JA” PÅ E. 10
RING RUNDT
”NEI” PÅ E. 10
RING RUNDT
”JA” PÅ E. 10
RING RUNDT
”NEI” PÅ E. 10
RING RUNDT
”JA” PÅ E. 10
RING RUNDT
”NEI” PÅ F. 1
RING RUNDT
”JA” PÅ F. 7
RING RUNDT
”NEI” PÅ F. 7
RING RUNDT
”JA” PÅ F. 1
RING RUNDT
”NEI” PÅ F. 11
RING RUNDT
”JA” PÅ F. 11
Er det andre ting du var spesielt redd for, slik som å fly, se blod 1   2
3 P7
ta sprøyte, lukkede rom, eller enkelte typer dyr eller insekter?
1=ikke tilstedeværende eller falsk 2=subterskel 3=terskel eller ekte
SCID-1 Versjon 2.0 (for DSM-IV) (Jan 1995 endelig) Silingsspørsmål Siling  - Side2
Har du noensinne vært plaget av tanker som virket meningsløse og som 1   2
3 P8
kom tilbake til deg selv om du prøvde å stenge dem ute?
Var det enkelte ting du måtte gjøre om og om igjen og som du ikke 1   2
3 P2
kunne stå i mot, slik som å vaske hendene dine igjen og igjen, telle
opp til ett bestemt tall, eller sjekke noe mange ganger for å være
sikker på at du hadde gjort det riktig?
Har du vært spesielt nervøs eller engstelig i løpet av de siste 1   2
3 P3
seks månedene?
Har du noensinne opplevd en periode hvor du veide mye mindre 1   2
3 P4
enn hva andre folk syntes du burde veie?
Har du ofte opplevd perioder hvor spisingen din var ukontrollert? 1   2
3 P5
1=ikke tilstedeværende eller falsk 2=subterskel 3=terskel eller ekte
RING RUNDT
”NEI” PÅ F. 16
RING RUNDT
”JA” PÅ F. 16
RING RUNDT
”NEI” PÅ F. 20
RING RUNDT
”JA” PÅ F. 20
RING RUNDT
”NEI” PÅ F. 21
RING RUNDT
”JA” PÅ F. 31
RING RUNDT
”NEI” PÅ F.31
RING RUNDT
”JA” PÅ F. 21
RING RUNDT
”NEI” PÅ H. 1
RING RUNDT
”JA” PÅ H. 4
RING RUNDT
”NEI” PÅ H. 4
RING RUNDT
”JA” PÅ H. 1
Tillegg screening SCID-I silingsmodul:
1.Stimulantia/Rusmidler
Har du noen gang i løpet av ditt liv drukket fem eller flere drinker (øl, vin eller sprit) ved en 
og samme anledning? Ja  Nei  
Hvor ofte har det skjedd?_________________________________________________
_____________________________________________________________________
 Alkohol   
Enheter (AE) pr uke: 0-5 5-10 10-15 mer enn 15 
Har drikkingen skapt problemer for deg eller andre?______________________________
________________________________________________________________________
2. Har du noensinne brukt ulovlige narkotiske stoffer?
Ja Nei 
Over tid?________________________________________________________________ 
________________________________________________________________________
________________________________________________________________________
Hvor mye?______________________________________________________________
___________________________________________________________________________
_____________________________________________________________________
Hva slags stoffer?
___________________________________________________________________________
___________________________________________________________________________
__________________________________________________________________
Andre rusmidler/blanding:
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
_______________________________________________________________
Er det historie med alkohol og /eller rusmisbruk i familie/nær slekt?
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
13. Somatisering/somatoform (G.1)
Har du før du ble 30 år hatt en del plagsomme symptomer der legen din 1     2     3 
ikke kunne finne at noe var galt/fant ut hva det skyldtes? (3= gå til G.1)
14. PTSD (F.25)
Har du opplevd traumatiske hendelser, sånn som å være i en livstruende situasjon, stor 
katastrofe, veldig alvorlig ulykke eller brann, blitt overfalt eller voldtatt, se en annen person 
bli drept eller som er død og hardt skadet, eller høre om noe grusomt som har skjedd dine 
nærmeste. Har noe slikt hendt deg i løpet av ditt liv?
1     2     3
(3=gå til F.25)
15. Psykotiske og assosierte symptomer (B.1)
Vrangforestillinger:
Har du hatt uvanlige opplevelser som folk av og til har?
- å motta spesielle beskjeder gjennom tv, radio eller aviser, eller ut fra måten ting var plassert 
rundt deg? (selvhenførende vf)
- at noen aktivt har gått inn for at du skulle komme opp i vanskeligheter eller forsøkt å såre 
deg?(forfølgelses vf)
- at du var veldig betydningsfull på en eller annen måte, eller at du hadde makt til å gjøre ting 
andre ikke kunne? (grandiose vf)
- at det var noen veldig galt med kroppen din selv om legen sa at det ikke var noe i veien med 
deg, som for eksempel at du hadde kreft eller en annen alvorlig sykdom? (somatisk vf)
- hatt noen uvanlige religiøse opplevelser eller følt at du har begått en forbrytelse eller gjort 
noe forferdelig som du burde straffes for? (religiøst, sjalusi, skyld)
- at noen eller noe utenfor deg selv kontrollerte tankene eller handlingene mot din vilje? 
(tanker påført av andre, tanketyveri)
Hallusinasjoner
dvs. se, høre eller kjenne på kroppen eller huden noe andre ikke kunne se/høre/kjenne?
Hvis treff på noen av disse, gå til B.1 
Trettbarhet : POST-testing
Hvordan vil du beskrive ditt nåværende nivå av generell trettbarhet? 
(eks. nedsatt energi fysisk og psykisk, utmattelse)
Ingen Meget svakt Svakt Moderat Sterkt      Meget sterkt
